Treatment for non-alcoholic fatty liver disease
Novel compounds and drug combinations address the unmet need for effective NAFLD and NASH treatment by reducing liver fat, inflammation, and fibrosis, offering improved liver health outcomes.
Patent Information
- Application Number
- JP2024152701
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-09-18
- Filing Date
- 2024-09-04
- Publication Date
- 2024-11-21
AI Technical Summary
There is an unmet need for effective treatments and prevention of nonalcoholic fatty liver disease (NAFLD), particularly nonalcoholic steatohepatitis (NASH), due to the limitations of current pharmacological agents and the risks associated with existing therapies such as vitamin E and pioglitazone, and the absence of FDA-approved medications.
The use of novel compounds, including specific formulations and combinations with additional drugs, to treat or prevent NAFLD and NASH by reducing symptoms such as liver fat accumulation, inflammation, and fibrosis through therapeutic administration.
The proposed methods effectively reduce liver fat, inflammation, and fibrosis, improving liver function and potentially preventing complications like cirrhosis and hepatocellular carcinoma, while minimizing adverse effects.
Smart Images

Figure 2024163257000001_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to and the benefit of co-pending U.S. Provisional Patent Application No. 62 / 732,644, filed September 18, 2018, which is incorporated herein by reference in its entirety.
[0002] Technical Field The present invention relates generally to methods and related compositions for treating non-alcoholic fatty liver disease (NAFLD), and in particular non-alcoholic steatohepatitis (NASH), in a subject. [Background technology]
[0003] 2. Background of the Invention Nonalcoholic fatty liver disease (NAFLD), the hepatic manifestation of metabolic syndrome, is the most common chronic liver disease in the United States, affecting 75-100 million Americans (Rinella ME. JAMA 2015;313(22):2263-2273). With increasing caloric intake from richer diets and more sedentary lifestyles, more people in more parts of the world are now facing NAFLD as a serious threat to their health. Although NAFLD is closely related to obesity, type II diabetes and metabolic syndrome, the public health impact of NAFLD is significant due to the morbidity and mortality associated with it.
[0004] NAFLD, as an emerging global epidemic, has become the most common cause of abnormal liver function tests in clinical practice. NAFLD is present when more than 5% of hepatocytes have an excessive amount of fat in the liver of people who consume little or no alcohol (less than 20 g / day in women and less than 30 g / day in men). NAFLD has traditionally been viewed as a continuum of diseases that begins with a clinically benign steatosis (nonalcoholic fatty liver or NAFL) that can progress to more severe conditions such as nonalcoholic steatohepatitis (NASH). Patients with NASH are at high risk of developing other complications including fibrosis, cirrhosis and hepatocellular carcinoma (HCC) (Sanyal AJ. Nat Clin Pract Gastroenterol Hepatol 2005;2(1):46-53). Cirrhosis develops in 15-25% of patients with NASH (Matteoni CA, et al., Gastroenterology 1999;116(6):1413-1419. Bacon BR, et al., Gastroenterology 1994;107(4):1103-1109. Powell EE, et al., Hepatology 1990;11(1):74-80. Lee RG. Hum Pathol 1989;20(6):594-598.), and 30-40% of patients with cirrhosis will die from liver-related causes (Rinella ME. JAMA 2015;313(22):2263-2273). Thus, NASH is currently considered to be a progressive subtype of NAFLD, as hepatic steatosis with inflammation and hepatocellular injury has a more progressive natural history than isolated steatosis.
[0005] Currently, there are no medications approved by the Federal Drug Administration (FDA) or the European Medicines Agency (EMA) for the treatment of NAFLD or NASH, although there are a number of pharmacological agents involved in ongoing clinical trials (e.g., obeticholic acid, elafibranor, cenicriviroc, selonsertib). The cornerstone of all therapeutic efforts remains lifestyle intervention with weight loss. There are multiple studies showing that the degree of liver histological improvement is directly proportional to the amount of weight loss (Harrison SA et al., Hepatology 2009;49(1):80-86.Wong VW et al., J Hepatol 201 3;59(3):536-542). Current pharmacological agents with demonstrated efficacy in randomized clinical trials include vitamin E, pioglitazone and pentoxifylline. Vitamin E is the most commonly used medication in clinical practice; current AASLD and EASL guidelines recommend its use in nondiabetic noncirrhotic patients with NASH based on data generated in the PIVENS trial (Chalasani N et al., Hepatology 2017;67(1):328-357. European Association for the Study of the L et al., J Hepatol 2016;64(6):1388-1402. Sanyal AJ et al., N Engl J Med 2010;362(18):1675-1685). Nevertheless, safety concerns have been raised regarding the use of vitamin E, as it has been associated with an increased risk of death, prostate cancer, and hemorrhagic stroke (Bjelakovic G et al., JAMA 2007;297(8):842-857. Klein EA et al., JAMA 2011;306(14):1549-1556. Miller ER et al., Ann Intern Med 2005;142(1):37-46). The insulin sensitizer pioglitazone has also been prescribed to patients with NASH, with or without diabetes, with fairly consistent improvement in various features of NASH. Nevertheless, the main negative aspect of the use of this drug is the weight gain of 3-5 kg that occurs in 60-70% of patients (Sanyal AJ et al., N Engl J Med 2010;362(18):1675-1685. Musso G et al., Hepatology 2010;52(1):79-104). Pioglitazone should also not be used in patients with clinically evident heart failure (Nesto RW et al., Diabetes Care 2010;52(1):79-104). 2004;27(1):256-263). In addition, the drug has been associated with postmenopausal bone loss (Lecka-Czernik B.Curr Osteoporos Rep.2010;8(4):178-184). Pentoxifylline has been studied in two randomized clinical trials (Van Wagner LB et al., Ann Hepatol 2011;10(3):277-286. Zein CO et al., Hepatology 2011;54(5):1610-1619) suggesting histological benefit in NASH, including reduced liver fibrosis; however, these studies were small and the conclusions require further confirmation in larger trials. Although there is no complete understanding of the causes of NASH, insulin resistance and the accumulation of toxic lipid metabolites are thought to play important roles in its development (Filozof et al., Drugs 2015;75:1373-1392). Clearly, there continues to be an unmet need for effective treatments and / or prevention for NASH and other NAFLD-related conditions. [Prior art documents] [Non-patent literature]
[0006] [Non-Patent Document 1] Rinella ME.JAMA 2015;313(22):2263-2273 [Non-Patent Document 2] Sanyal AJ.Nat Clin Pract Gastroenterol Hepatol 2005;2(1):46-53 [Non-Patent Document 3] Matteoni CA et al. Gastroenterology 1999;116(6):1413-1419 [Non-Patent Document 4] Bacon BR et al. Gastroenterology 1994;107(4):1103-1109 [Non-Patent Document 5] Powell EE et al., Hepatology 1990;11(1):74-80 [Non-Patent Document 6] Lee RG. Hum Pathol 1989;20(6):594-598 [Non-Patent Document 7] Rinella ME.JAMA 2015;313(22):2263-2273 [Non-Patent Document 8] Harrison SA et al. Hepatology 2009;49(1):80-86 [Non-Patent Document 9] Wong VW et al., J Hepatol 2013;59(3):536-542 [Non-Patent Document 10] Chalasani N et al. Hepatology 2017;67(1):328-357 [Non-Patent Document 11] European Association for the Study of the L et al., J Hepatol 2016;64(6):1388-1402 [Non-Patent Document 12] Sanyal AJ et al. N Engl J Med 2010;362(18):1675-1685 [Non-Patent Document 13] Bjelakovic G et al. JAMA 2007;297(8):842-857 [Non-Patent Document 14] Klein EA et al., JAMA 2011;306(14):1549-1556 [Non-Patent Document 15] Miller ER et al. Ann Intern Med 2005;142(1):37-46 [Non-Patent Document 16] Sanyal AJ et al. N Engl J Med 2010;362(18):1675-1685 [Non-Patent Document 17] Musso G et al., Hepatology 2010;52(1):79-104 [Non-Patent Document 18] Nesto RW et al., Diabetes Care 2004;27(1):256-263 [Non-Patent Document 19] Lecka-Czernik B.Curr Osteoporos Rep.2010;8(4):178-184 [Non-Patent Document 20] Van Wagner LB et al., Ann Hepatol 2011;10(3):277-286.Zein CO et al., Hepatology 2011;54(5):1610-1619 [Non-Patent Document 21] Filozof et al. Drugs 2015;75:1373-1392 Summary of the Invention [Means for solving the problem]
[0007] The present invention addresses these needs. The present invention provides novel methods (embodiments detailed below) using the compounds of the present invention. In one aspect, the present invention provides a method for treating or preventing non-alcoholic fatty liver disease (NAFLD) in a mammal, including a human, comprising administering to a mammalian subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a compound of the present invention, or its enantiomer, diastereomer, tautomer, or pharma- ceutically acceptable salt, solvate, ester, or prodrug, which is effective in treating or preventing NAFLD in a mammal, including a human, and a pharma- ceutically acceptable excipient, carrier, or diluent.
[0008] In one aspect, the NAFLD is nonalcoholic steatohepatitis (NASH). In another aspect, the NAFLD is simple steatosis or fatty liver.
[0009] In one aspect, the present invention provides a method of reducing, ameliorating, or eliminating mortality or morbidity, including at least one symptom or sign known to be associated with NAFLD (e.g., NASH), in a mammal, including a human, comprising administering to a mammalian subject in need thereof at least one symptom or sign of NAFLD in a mammal, including a human. The present invention provides a method for treating rheumatoid arthritis, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound of the present invention or an enantiomer, diastereomer, tautomer, or a pharma- ceutically acceptable salt, solvate, ester, or prodrug thereof, and a pharma- ceutically acceptable excipient, carrier, or diluent, which is effective to reduce, ameliorate, or eliminate rheumatoid arthritis, inflammatory bowel disease, or rheumatoid arthritis.
[0010] In various embodiments, the symptom or sign known to be associated with NAFLD or NASH that is reduced, ameliorated or eliminated is selected from the group consisting of liver fat accumulation, elevated levels of liver triglycerides, liver fibrosis, lobular inflammation, ballooning of liver cells, elevated levels of the liver enzymes aspartate aminotransferase (AST) and / or alanine aminotransferase (ALT), and a NAFLD activity score (NAS) of greater than 3.
[0011] In one aspect, the method of the present invention further comprises the step of administering an additional agent selected from the group consisting of vitamins, lipid-lowering drugs, insulin sensitizers, anti-inflammatory drugs, cholesterol-lowering drugs, diabetes drugs, experimental anti-NASH agents, and weight loss drugs. The anti-inflammatory drug can be an antioxidant, an anti-apoptotic drug, or an anti-cytokine drug. The vitamin can be, for example, vitamin D or E. The experimental anti-NASH agent can be, for example: a farnesoid x receptor agonist, a PPAR agonist, an acetyl-CoA carboxylase (ACC), CC chemokine ligand type 2 and type 5 antagonist, an apoptosis signal-regulating kinase (ASK1) inhibitor, a lysyl oxidase-like 2 antibody, an anti-liver fibrosis agent, or a galectin-3 inhibitor.
[0012] In various embodiments, the compound of the invention is one of formulas IX as described below in the detailed description of the invention.
[0013] In various embodiments, the compound of the invention is one of the following eight compounds: Compound 5, Compound 7-1, Compound 18-5, Compound 18-2, Compound 13-3, Compound 9, Compound 12, and Compound 10-1, as described in more detail below.
[0014] In further embodiments, the compound of the invention is one of the following fifteen compounds described in more detail below: Compound 13-3-1, Compound 13-3-2, Compound 13-3-3, Compound 13-3-5, Compound 13-3-6, Compound 13-3-7, Compound 13-3-10, Compound 13-3-11, Compound 001, Compound 004, Compound 006, Compound 013, Compound 132, Compound 133 and Compound 134.
[0015] In yet another aspect, the present invention generally relates to pharmaceutical compositions comprising a compound disclosed herein, or a pharma- ceutically acceptable salt, solvate, ester, or prodrug thereof, and a pharma- ceutically acceptable excipient, carrier, or diluent, and uses thereof.
[0016] In one aspect, the invention generally relates to methods of treating a NASH patient using one or more compositions disclosed herein such that at least one of the symptoms associated with NASH is improved. Treatment may further include the additional step of evaluating the success of the treatment by evaluating the subject / patient before and during treatment. [Brief description of the drawings]
[0017] [Figure 1A-B]Figures 1A-1C show data on a study designed to investigate whether the compounds of the invention have any effect on triglyceride accumulation in human hepatocyte cultures. Figures 1A-1C show quantification data on intracellular triglyceride accumulation when various embodiments of the compounds of the invention are used in each given sample. Compound 13-3 (*: DMSO vs. compound 13-3 in the corresponding culture medium; #: control medium (left two columns) vs. palmitoleic acid (POA) medium (right two columns); p<0.05) (Figure 1A); effects from nine other embodiments in POA medium compared to the effect of compound 13-3 (Figure 1B); effects from seven different embodiments in POA medium compared to the effect of compound 13-3 (Figure 1C). [Figure 1C] Figures 1A-1C show data on a study designed to investigate whether the compounds of the invention have any effect on triglyceride accumulation in human hepatocyte cultures. Figures 1A-1C show quantification data on intracellular triglyceride accumulation when various embodiments of the compounds of the invention are used in each given sample. Compound 13-3 (*: DMSO vs. compound 13-3 in the corresponding culture medium; #: control medium (left two columns) vs. palmitoleic acid (POA) medium (right two columns); p<0.05) (Figure 1A); effects from nine other embodiments in POA medium compared to the effect of compound 13-3 (Figure 1B); effects from seven different embodiments in POA medium compared to the effect of compound 13-3 (Figure 1C).
[0018] [Figure 2A-B] Figures 2A-2E present in vivo animal data regarding (2A) changes in body weight during compound 13-3 treatment; (2B) body weight at euthanasia; compound 13-3-induced weight loss in HFD-fed mice was not associated with reduced food intake (2C) or water intake (2D); (2E) gross overview of the liver at euthanasia with or without treatment with compound 13-3. [Figure 2C-D]Figures 2A-2E present in vivo animal data regarding (2A) changes in body weight during compound 13-3 treatment; (2B) body weight at euthanasia; compound 13-3-induced weight loss in HFD-fed mice was not associated with reduced food intake (2C) or water intake (2D); (2E) gross overview of the liver at euthanasia with or without treatment with compound 13-3. [Figure 2E] Figures 2A-2E present in vivo animal data regarding (2A) changes in body weight during compound 13-3 treatment; (2B) body weight at euthanasia; compound 13-3-induced weight loss in HFD-fed mice was not associated with reduced food intake (2C) or water intake (2D); (2E) gross overview of the liver at euthanasia with or without treatment with compound 13-3.
[0019] [Figure 3A] 3A-3C present in vivo animal data regarding (3A) gross liver appearance, (3B) reduction in liver weight, and (3C) comparison of liver / body weight ratios at the time of euthanasia showing significant amelioration of NAFLD / NASH pathology with compound 13-3 treatment. [Figure 3B-C] 3A-3C present in vivo animal data regarding (3A) gross liver appearance, (3B) reduction in liver weight, and (3C) comparison of liver / body weight ratios at the time of euthanasia showing significant amelioration of NAFLD / NASH pathology with compound 13-3 treatment.
[0020] [Figure 4] Figure 4 shows micrographs of harvested mouse liver samples stained with (top) hematoxylin-eosin, (middle) Masson's trichrome, (bottom) periodic acid-Schiff. The left column shows negative control samples. The center column shows HFD-fed mice and vehicle-treated mice; the right column shows HFD-fed mice treated with compound 13-3.
[0021] [Figure 5A-B]5A-5D present in vivo animal data on (5A) HFD-induced steatosis and lobular inflammation suppressed by a compound of the invention, compound 13-3; (5B) elimination of HFD-induced hepatocyte ballooning by compound 13-3; (5C) NAS score lowered by compound 13-3 and (5D) collagen type I, alpha 1 gene expression inhibited in liver by compound 13-3. [Figure 5C-D] 5A-5D present in vivo animal data on (5A) HFD-induced steatosis and lobular inflammation suppressed by a compound of the invention, compound 13-3; (5B) elimination of HFD-induced hepatocyte ballooning by compound 13-3; (5C) NAS score lowered by compound 13-3 and (5D) collagen type I, alpha 1 gene expression inhibited in liver by compound 13-3.
[0022] [Figure 6A-B] Figures 6A-6D present in vivo animal data showing that (6A) compound 13-3 reduces hepatic triglyceride content; (6B) compound 13-3 inhibits ALT elevation as an indicator of liver injury; (6C) AST is unaffected by HFD or compound 13-3 treatment; and (6D) the decrease in AST:ALT ratio is inhibited by compound 13-3 treatment. [Figure 6C-D] Figures 6A-6D present in vivo animal data showing that (6A) compound 13-3 reduces hepatic triglyceride content; (6B) compound 13-3 inhibits ALT elevation as an indicator of liver injury; (6C) AST is unaffected by HFD or compound 13-3 treatment; and (6D) the decrease in AST:ALT ratio is inhibited by compound 13-3 treatment.
[0023] [Figure 7] Figures 7A-7E present in vivo animal data regarding gene expression levels of CPT1a (7A), ACOX1 (7B) and FGF21 (7C), serum FGF21 levels (7D) and serum leptin levels (7E).
[0024] [Figure 8] 8A-8D present in vivo animal data regarding gene expression levels of PPAR-γ (8A), protein expression of PPAR-γ in the liver (8B), gene expression levels of FABP4 (8C) and CD36 (8D). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0025] definition As used in this specification and claims, the singular forms "a," "an," or "the" include plural referents unless the context clearly dictates to the contrary. For example, the term "a cell" includes a plurality of cells, including mixtures of cells.
[0026] As used herein, the terms "about" or "approximately" when used in conjunction with a number refer to any number within 5, 10 or 15% of the referenced number.
[0027] As used herein, the term "subject" refers to any animal (e.g., mammal), including but not limited to humans, non-human primates, rodents, dogs, etc., that will be the recipient of a particular treatment. Typically, the terms "subject" and "patient" are used interchangeably herein in reference to human subjects.
[0028] As used herein, "nonalcoholic fatty liver," "fatty liver," "steatosis," or "NAFL" refers to the presence of hepatic steatosis without evidence of hepatocellular injury in the form of hepatocyte ballooning.
[0029] As used herein, "nonalcoholic steatohepatitis" or "NASH" is defined as the presence of hepatic steatosis and inflammation (steatohepatitis) with hepatocellular injury (ballooning) with or without fibrosis. Nonalcoholic steatohepatitis can progress to cirrhosis, liver failure, and even liver cancer. Currently, NASH is diagnosed after imaging tests (such as ultrasound, CT scan, or magnetic resonance imaging [MRI]) that reveal fat accumulation in the liver, and blood or liver function tests that show elevated levels of two liver enzymes (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]). Multiple biomarkers are being evaluated for the noninvasive diagnosis of NASH. However, However, percutaneous liver biopsy remains the gold standard for confirming the diagnosis, and minimum diagnostic criteria include the presence of >5% macrovesicular steatosis, inflammation, and hepatocyte ballooning. In some cases, fibroscan is used as a non-invasive alternative to liver biopsy to diagnose NASH. Fibroscan uses ultrasound to determine how "stiff" the liver is, and therefore how much scarring is present in the liver, and whether cirrhosis has developed.
[0030] A composite NAS score is often used to describe the severity or characterize the pathological changes observed in NAFLD (Kleiner DE et al., Hepatology. 2005 41(6):1313-21). The NAS score includes scoring for steatosis, lobular inflammation and hepatocyte ballooning / injury. An NAS score of 5-8 is primarily considered diagnostic of NASH, whereas a score of 3-4 is often considered borderline and a score of 0-2 is considered negative for NASH.
[0031] As used herein, the terms "treat", "treating" and "treatment" have their ordinary and customary meanings, including one or more of blocking, ameliorating or reducing the severity, frequency and / or progression of symptoms of a disease or condition (e.g., NAFLD), or inducing regression or stasis of a disorder or disease in a subject. Treatment means blocking, ameliorating, reducing or inhibiting by about 1% to about 100% relative to a subject in which the method of the invention is not performed. Preferably, blocking, ameliorating, reducing or inhibiting is about 100%, 95%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10% or 5% relative to a subject in which the method of the invention is not performed. Treatment can be for an existing condition or can be prophylactic against a future condition.
[0032] As used herein, the terms "inhibit", "inhibiting" and their grammatical equivalents, when used in the context of biological activity, refer to the downregulation of biological activity, which can reduce or eliminate the targeted function, such as the production of a protein or the phosphorylation of a molecule. In certain embodiments, inhibition can refer to a reduction of about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95% of the targeted activity. When used in the context of a disorder or disease, these terms refer to the success of preventing or significantly delaying the onset of symptoms, alleviating symptoms, or eliminating a disease, condition or disorder.
[0033] As used herein, the terms "administration", "administering", and the like, when used in the context of providing a pharmaceutical composition to a subject, generally refer to providing a subject with one or more pharmaceutical compositions comprising a compound of the present invention in combination with a suitable delivery vehicle by any means such that the administered compound achieves one or more of the intended biological effects for which the compound was administered. As non-limiting examples, the compositions can be administered parenterally, subcutaneously, intravenously, intracoronary, rectally, intramuscularly, intraperitoneally, transdermally, or via buccal delivery routes.
[0034] Definitions of specific functional groups and chemical terms are described in more detail below. General principles of organic chemistry, as well as specific functional moieties and reactivities, are described in "Organic Chemistry", by Thomas Sorrell, University Science Books, Sausalito: 2006.
[0035] Certain compounds of the present invention may exist in specific geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis and trans isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the present invention. Additional asymmetric carbon atoms may be present in substituents such as alkyl groups. All such isomers and mixtures thereof are intended to be included in the present invention.
[0036] Isomeric mixtures containing any of a variety of isomeric ratios can be utilized according to the present invention. For example, when only two isomers are combined, mixtures containing isomeric ratios of 50:50, 60:40, 70:30, 80:20, 90:10, 95:5, 96:4, 97:3, 98:2, 99:1 or 100:0 are contemplated by the present invention. Those skilled in the art will readily recognize that similar ratios are contemplated for more complex isomeric mixtures.
[0037] For example, if a particular enantiomer of a compound of the invention is desired, it may be prepared by asymmetric synthesis or by derivatization with a chiral auxiliary where the resulting diastereomeric mixture is separated and the auxiliary group is cleaved to provide the desired pure enantiomer. Alternatively, if the molecule contains a basic functional group such as amino or an acidic functional group such as carboxyl, a diastereomeric salt may be formed with an appropriate optically active acid or base, and the diastereomers thus formed may then be resolved by fractional crystallization or chromatographic methods well known in the art, followed by recovery of the pure enantiomer.
[0038] With the benefit of this disclosure, one of skill in the art will recognize that the synthetic methods as described herein may utilize a variety of protecting groups. The term "protecting group," as used herein, means that a particular functional moiety (e.g., O, S, or N) is temporarily blocked to allow a reaction to be selectively performed at another reactive site in a multifunctional compound. In preferred embodiments, the protecting group reacts selectively in good yield to give a protected substrate that is stable for the planned reaction; the protecting group should be selectively removable in good yield by a reagent that does not attack other functional groups, preferably a readily available non-toxic reagent; the protecting group forms a derivative that is easily separable (more preferably, without creating new asymmetric centers); the protecting group has minimal additional functionality to avoid further reactive sites. Oxygen, sulfur, nitrogen, and carbon protecting groups may be utilized. Examples of various protecting groups can be found in "Protective Groups in Organic Synthesis," 3rd Edition, Greene, TW and Wilson, J. Med., 1999, 144:131-135, 1999. Wuts, PG, Eds., John Wiley & Sons, New York: 1999.
[0039] It is understood that the compounds as described herein may be substituted with any number of substituents or functional moieties. Throughout the specification, groups and substituents thereof may be chosen to provide stable moieties and compounds.
[0040] As used herein, the term "effective amount" of an active agent refers to an amount sufficient to induce a desired biological response.As will be understood by those skilled in the art, the effective amount of the compound of the present invention may vary depending on factors such as the desired biological endpoint, the pharmacokinetics of the compound, the disease to be treated, the mode of administration and the patient.
[0041] As used herein, the term "pharmaceutically acceptable salt" means either a pharmaceutically acceptable acid addition salt or a pharmaceutically acceptable base addition salt of the presently disclosed compounds, which may be administered without any substantial undesired biological effects or without any deleterious interactions with any other components of the pharmaceutical composition in which it may be included.
[0042] The compounds of the present invention may form salts that are also within the scope of the present invention. Reference to the compounds of the present invention herein is understood to include reference to their salts, unless otherwise indicated. The term "salts" as used herein means acidic and / or basic salts formed with inorganic and / or organic acids and bases. Furthermore, when the compounds of the present invention contain both a basic moiety, such as, but not limited to, pyridine or imidazole, and an acidic moiety, such as, but not limited to, carboxylic acid, zwitterions ("inner salts") may be formed, which are included in the term "salts" as used herein. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, although other salts are also useful, e.g., in separation or purification steps that may be employed during preparation. Salts of the compounds of the present invention can be formed, for example, by reacting Compound I, II, or III with an equivalent amount, or the like, of an acid or base in a medium such that the salt precipitates, or in an aqueous medium (followed by lyophilization).
[0043] The compounds of the present invention that contain a basic moiety, such as, but not limited to, an amine or a pyridine or imidazole ring, can form salts with a variety of organic and inorganic acids. Exemplary acid addition salts include acetate (such as those formed with acetic acid or a trihaloacetic acid, e.g., trifluoroacetic acid), adipate, alginate, ascorbate, aspartate, benzoate, benzenesulfonate, bisulfate, borate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, hydroxyl, hydroxypropyl ... These include ethanesulfonates (e.g., 2-hydroxyethanesulfonate), lactate, maleate, methanesulfonate, naphthalenesulfonate (e.g., 2-naphthalenesulfonate), nicotinate, nitrate, oxalate, pectinate, persulfate, phenylpropionate (e.g., 3-phenylpropionate), phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate (such as that formed with sulfuric acid), sulfonate, tartrate, thiocyanate, toluenesulfonate such as tosylate, undecanoate, and the like.
[0044] Compounds of the invention that contain an acid moiety, such as, but not limited to, a carboxylic acid, can form salts with a variety of organic and inorganic bases. Exemplary base salts include ammonium salts, alkali metal salts such as sodium, lithium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (e.g., organic amines) such as benzathine, dicyclohexylamine, hydrabamine (formed with N,N-bis(dehydroabietyl)ethylenediamine), N-methyl-D-glucamine, N-methyl-D-glycamide, t-butylamine, and salts with amino acids such as arginine, lysine, and the like. Basic nitrogen-containing groups may be quaternized with agents such as lower alkyl halides (e.g., methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides), dialkyl sulfates (e.g., dimethyl, diethyl, dibutyl, and cyamyl sulfate), long chain halides (e.g., decyl chloride, bromide, and iodides, lauryl, myristyl, and stearyl), aralkyl halides (e.g., benzyl and phenethyl bromides), and others.
[0045] As used herein, the term "pharmaceutical acceptable ester" refers to an ester that hydrolyzes in vivo, including those that are easily decomposed in the human body to release the parent compound or its salt.Suitable ester groups include, for example, those derived from pharmaceutical acceptable aliphatic carboxylic acids, particularly alkanoic acids, alkenoic acids, cycloalkanoic acids and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has 6 or less carbon atoms.Specific examples of esters include formates, acetates, propionates, butyrates, acrylates and ethylsuccinates.
[0046] As used herein, the term "prodrug" refers to a pharmacological derivative of a parent drug molecule that requires biotransformation, either spontaneously or enzymatically, in an organism to release the active drug. For example, a prodrug is a variant or derivative of a compound of formula I that has groups cleavable under certain metabolic conditions, which, when cleaved, yields a compound of formula I. Such prodrugs then undergo solvolysis under physiological conditions or are enzymatically degraded. Prodrug compounds become pharma- ceutical active in vivo upon undergoing elementary degradation. As used herein, prodrug compounds may be referred to as single, double, triple, etc., depending on the number of biotransformation steps required to release the active drug and the number of functional groups present in the precursor form.
[0047] Prodrug forms often offer advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (Bundgard, Design of Prodrugs, pp. 7-9,21-24, Elsevier, Amsterdam 1985 and Silverman, The Organic Chemistry of Drug Design, pp. 117-119, 2001). and Drug Action, pp. 352-401, Academic Press, San Diego, Calif., 1992). Examples of prodrugs generally known in the art include, for example, Examples of prodrug derivatives include well-known acid derivatives such as esters prepared by reaction of a carboxylic acid with an appropriate alcohol, amides prepared by reaction of the parent acid compound with an amine, and basic groups reacting to form acylated basic derivatives. Of course, other prodrug derivatives may be combined with other features disclosed herein to enhance bioavailability. Thus, one skilled in the art will recognize that certain of the compounds disclosed herein that have free amino, amide, hydroxy, or carboxylic acid groups may be converted to prodrugs. Prodrugs include compounds having amino acid residues or polypeptide chains of two or more (e.g., 2, 3, or 4) amino acid residues covalently bonded by peptide bonds to free amino, hydroxy, or carboxylic acid groups of the compounds disclosed herein. Amino acid residues include the 20 naturally occurring amino acids, commonly designated by their three-letter code, and also 4-hydroxyproline, hydroxylysine, desmosine, isodesmosine, 3-methylhistidine, 4-methylhistidine, 5-methylhistidine, 6-methylhistidine, 7-methylhistidine, 8-methylhistidine, 9-methylhistidine, 10-methylhistidine, 11-methylhistidine, 12-methylhistidine, 13-methylhistidine, 14-methylhistidine, 15-methylhistidine, 16-methylhistidine, 17-methylhistidine, 18-methylhistidine, 19-methylhistidine, 20-methylhistidine, 21-methylhistidine, 22-methylhistidine, 23-methylhistidine, 24-methylhistidine, 25-methylhistidine, 26-methylhistidine, 27-methylhistidine, 28-methylhistidine, 29-methylhistidine, 30-methylhistidine, 31-methylhistidine, 32-methylhistidine, 33-methyl Prodrugs include cysteine, norvaline, β-alanine, γ-aminobutyric acid, citrulline homocysteine, homoserine, ornithine, and methionine sulfone. Prodrugs also include compounds having a carbonate, carbamate, amide, or alkyl ester moiety covalently bonded to any of the above substituents disclosed herein.
[0048] The term "pharmaceutically acceptable excipient, carrier or diluent" as used herein means a pharma- ceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, required to carry or transport a subject drug from one organ or part of the body to another. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not harmful to the patient. Some examples of substances which can function as pharma- ceutically acceptable carriers are sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; celluloses and their derivatives such as sodium carboxymethylcellulose, ethylcellulose and cellulose acetate; excipients such as powdered tragacanth, malt, gelatin, talc, cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols such as propylene glycol; polyols such as glycerin, sorbitol, mannitol and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar, buffers such as magnesium hydroxide and aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethyl alcohol, phosphate buffers, and other non-toxic compatible substances used in pharmaceutical formulations. Wetting agents, emulsifiers and lubricants such as sodium lauryl sulfate, magnesium stearate, and polyethylene oxide-polypropylene oxide copolymers, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives, and antioxidants may also be present in the composition.
[0049] As used herein, "C x ~C y The term "C1-C6" generally refers to a group having from x to y carbon atoms. Thus, for example, "C1-C6" refers to a group having 1, 2, 3, 4, 5 or 6 carbon atoms, which includes C1-C2, C1-C3, C1-C4, C1-C5, C2-C3, C2-C4, C2-C5, C2 ~C6, and all similar combinations. 20 " etc. are similarly C1~C6, C1~C 12 and C3~C 12 and the like, including various combinations of between 1 and 20 (1 or more and 20 or less) carbon atoms.
[0050] As used herein, the term "alkyl" refers to a straight or branched chain alkane (hydrocarbon) group. Exemplary "alkyl" groups include methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl, and the like. "Substituted alkyl" refers to an alkyl group substituted with one or more substituents, preferably 1 to 4 substituents, at any available point of attachment. Exemplary substituents include one or more of the following groups: hydrogen, halogen (e.g., one halogen substituent or multiple halo substituents, in the latter case forming groups such as an alkyl group with CF3 or Cl3), cyano, nitro, CF3, OCF3, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, aryl, OR, aryl ... a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR d , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NRb R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)R e Including, but not limited to, where R a is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle or aryl; R b , R c and R d are independently hydrogen, alkyl, cycloalkyl, heterocycle, aryl, or optionally b and R c form a heterocycle or a substituted heterocycle together with the N to which they are attached, and R e is alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, or aryl. In the above exemplary substituents, groups such as alkyl, cycloalkyl, alkenyl, alkynyl, cycloalkenyl, heterocycle, and aryl may themselves be optionally substituted. As used herein, the term "C x ~C y The term "alkyl" means a saturated straight or branched chain radical consisting essentially of x to y carbon atoms, where x is an integer from 1 to about 10 and y is an integer from about 2 to about 20. x ~C y The alkyl group is C1 to C 20 "Alkyl" and "C1-C 20 "Alkyl" means a saturated linear or branched radical consisting essentially of 1 to 20 carbon atoms and the corresponding number of hydrogen atoms.20 Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, and dodecanyl. Of course, other C1-C 20 Alkyl groups will be readily apparent to those of skill in the art given the benefit of this disclosure. The term "alkyl" refers to any group selected from C1 to C6. 20 and preferably C1 to C 10 More preferably, it is C1 to C6, and further preferably, it is C1 to C6.
[0051] As used herein, the term "alkenyl" refers to a straight or branched chain hydrocarbon group having at least one carbon-carbon double bond. Exemplary such groups include ethenyl or allyl. "Substituted alkenyl" refers to an alkenyl group substituted with one or more substituents, preferably 1 to 4 substituents, at any available point of attachment. Exemplary substituents include, but are not limited to, alkyl or substituted alkyl, as well as those groups recited above as exemplary alkyl substituents. Exemplary substituents may themselves be optionally substituted. The term "alkenyl" refers to an alkenyl group having a C2-C 20 and preferably C2 to C 10 and more preferably C2 to C6.
[0052] As used herein, the term "alkynyl" refers to a straight or branched chain hydrocarbon group having at least one carbon-carbon triple bond. Exemplary such groups include ethynyl. "Substituted alkynyl" refers to an alkynyl group substituted with one or more substituents, preferably 1 to 4 substituents, at any available point of attachment. Exemplary substituents include, but are not limited to, alkyl or substituted alkyl, as well as those groups recited above as exemplary alkyl substituents. Exemplary substituents may themselves be optionally substituted. The term "alkynyl" refers to a C2-C6 alkyl group. 20 and preferably C2 to C 10 and more preferably C2 to C6.
[0053] As used herein, the term "aryl" refers to a cyclic aromatic hydrocarbon group having one to five aromatic rings, particularly a monocyclic or bicyclic group such as phenyl, biphenyl, or naphthyl. When containing two or more aromatic rings (e.g., bicyclic), the aromatic rings of the aryl group may be attached at one point (e.g., biphenyl) or fused (e.g., naphthyl, phenanthrenyl, etc.). "Substituted aryl" or "substituted phenyl" refers to an aryl or phenyl group substituted at any point of attachment with one or more substituents, preferably one to three substituents. Exemplary substituents include, but are not limited to, nitro, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, cyano, alkyl or substituted alkyl, as well as the groups recited above as exemplary alkyl substituents. Exemplary substituents may themselves be optionally substituted. Exemplary substituents also include fused ring groups, particularly fused cycloalkyl, fused cycloalkenyl, fused heterocycle, or fused aryl, where the aforementioned cycloalkyl, cycloalkenyl, heterocycle, and aryl substituents can themselves be optionally substituted.
[0054] As used herein, the term "cycloalkyl" refers to a fully saturated cyclic hydrocarbon group having 1 to 4 rings and 3 to 10 carbons per ring. Exemplary such groups are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like. "Substituted cycloalkyl" refers to a cycloalkyl group substituted at any available point of attachment with one or more substituents, preferably 1 to 4 substituents. Exemplary substituents include, but are not limited to, nitro, cyano, alkyl or substituted alkyl, as well as the groups recited above as exemplary alkyl substituents. Exemplary substituents may themselves be optionally substituted. Exemplary substituents also include spiro-linked or fused cyclic substituents, particularly spiro-linked cycloalkyl, spiro-linked cycloalkenyl, spiro-linked heterocycle (excluding heteroaryl), fused cycloalkyl, fused cycloalkenyl, fused heterocycle, or fused aryl, the foregoing cycloalkyl, cycloalkenyl, heterocycle, and aryl substituents may themselves be optionally substituted. The term "cycloalkyl" refers to a C3-C6 alkyl group. 10 and preferably C3 to C8, and more preferably C3 to C6.
[0055] As used herein, the term "cycloalkenyl" refers to a partially unsaturated cyclic hydrocarbon group containing 1 to 4 rings and 3 to 10 carbons per ring. Exemplary such groups include cyclobutenyl, cyclopentenyl, cyclohexenyl, and the like. "Substituted cycloalkenyl" refers to a cycloalkenyl group substituted with one or more substituents, preferably 1 to 4 substituents, at any available point of attachment. Exemplary substituents include, but are not limited to, nitro, cyano, alkyl or substituted alkyl, as well as the groups recited above as exemplary alkyl substituents. Exemplary substituents may themselves be optionally substituted. Exemplary substituents also include spiro-linked or fused ring substituents, particularly spiro-linked cycloalkyls, spiro-linked cycloalkenyls, spiro-linked heterocycles (excluding heteroaryls), fused cycloalkyls, fused cycloalkenyls, fused heterocycles, or fused aryls, and the foregoing cycloalkyls and fused aryls may be substituted or fused with cycloalkyls and fused aryls. The aryl, cycloalkenyl, heterocycle and aryl substituents may themselves be optionally substituted. The term "cycloalkenyl" refers to any C3-C 10 and preferably C3 to C8, and more preferably C3 to C6.
[0056] As used herein, the term "heterocycle" or "heterocyclic" refers to fully saturated or partially or fully unsaturated, including aromatic (i.e., "heteroaryl") cyclic groups (e.g., 4- to 7-membered monocyclic, 7- to 11-membered bicyclic, or 8- to 16-membered tricyclic systems) having at least one heteroatom in at least one carbon atom-containing ring. Each ring of the heteroatom-containing heterocyclic group may have 1, 2, 3, or 4 heteroatoms selected from nitrogen, oxygen, and / or sulfur atoms, the nitrogen and sulfur heteroatoms optionally being oxidized, and the nitrogen heteroatom optionally being quaternized. (The term "heteroarylium" refers to a heteroaryl group having a quaternary nitrogen atom, and thus a positive charge.) The heterocyclic group may be attached to any heteroatom or carbon atom of the ring or ring system of the remainder of the molecule. Exemplary monocyclic heterocyclic groups are azetidinyl, pyrrolidinyl, pyrrolyl, pyrazolyl, oxetanyl, pyrazolinyl, imidazolyl, imidazolinyl, imidazolidinyl, oxazolyl, oxazolidinyl, isoxazolinyl, isoxazolyl, thiazolyl, thiadiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, furyl, tetrahydrofuryl, thienyl, oxadiazolyl, piperidinyl, piperazinyl, 2-oxopipera dioxolane, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, hexahydrodiazepinyl, 4-piperidonyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, triazolyl, tetrazolyl, tetrahydropyranyl, morpholinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, 1,3-dioxolane, and tetrahydro-1,1-dioxothienyl.Exemplary bicyclic heterocyclic groups are indolyl, isoindolyl, benzothiazolyl, benzoxazolyl, benzoxadiazolyl, benzothienyl, benzo[d][1,3]dioxolyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, quinuclidinyl, quinolinyl, tetrahydroisoquinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, indolizinyl, benzofuryl, benzofurayl, and the like. Exemplary tricyclic heterocyclic groups include carbazolyl, benzyl, chromonyl, coumarinyl, benzopyranyl, cinnolinyl, quinoxalinyl, indazolyl, pyrrolopyridyl, furopyridinyl (such as furo[2,3-c]pyridinyl, furo[3,2-b]pyridinyl or furo[2,3-b]pyridinyl), dihydroisoindolyl, dihydroquinazolinyl (such as 3,4-dihydro-4-oxoquinazolinyl), triazinylazepinyl, tetrahydroquinolinyl, and the like. Exemplary tricyclic heterocyclic groups include carbazolyl, benzidolyl, phenanthrolinyl, acridinyl, phenanthridinyl, xanthenyl, and the like.
[0057] As used herein, "substituted heterocycle" and "substituted heterocyclic" (e.g., "substituted heteroaryl") refer to a heterocycle or heterocyclic group substituted with one or more substituents, preferably 1 to 4 substituents, at any available point of attachment. Exemplary substituents include, but are not limited to, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, nitro, oxo (i.e., =O), cyano, alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, as well as those groups recited above as exemplary alkyl substituents. Exemplary substituents may themselves be optionally substituted. Exemplary substituents also include spiro-linked or fused ring substituents, particularly spiro-linked cycloalkyl, spiro-linked cycloalkenyl, spiro-linked heterocycle (excluding heteroaryl), fused cycloalkyl, fused cycloalkenyl, fused heterocycle, or fused aryl, at any available point of attachment or points, and the foregoing cycloalkyl, cycloalkenyl, heterocycle, and aryl substituents may themselves be optionally substituted.
[0058] As used herein, the term "halogen" means fluorine (F), chlorine (Cl), bromine (Br) or iodine (I).
[0059] The term "carbocyclic" refers to aromatic or non-aromatic 3- to 7-membered monocyclic and 7- to 11-membered bicyclic groups in which all atoms of the ring or rings are carbon atoms. "Substituted carbocyclic" refers to a carbocyclic group substituted with one or more substituents, preferably 1 to 4 substituents, at any available point of attachment. Exemplary substituents are nitro, cyano, OR, aryl ... a (R a is as defined above), as well as those groups recited above as exemplary cycloalkyl substituents. The exemplary substituents may themselves be optionally substituted.
[0060] Unless otherwise noted, any heteroatom with unsatisfied valences is presumed to have sufficient hydrogen atoms to satisfy the valences.
[0061] Isotopically labeled compounds are also within the scope of this disclosure.As used herein, "isotopically labeled compounds" refers to compounds disclosed herein, including pharmaceutical salts and prodrugs thereof, each as described herein, in which one or more atoms are replaced by atoms with atomic masses or mass numbers different from those usually found in nature.Examples of isotopes that can be incorporated into compounds disclosed herein include, respectively, pharmaceutical salts and prodrugs thereof, each as described herein. 2 H, 3 H, 13 C. 14 C. 15 N, 18 O. 17 O. 31 P, 32 P, 35 S, 18 F and 36 Included are isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as Cl.
[0062] By isotopically labelling the compounds disclosed herein, the compounds may be useful in drug and / or substrate tissue distribution assays. 3 H) and carbon-14 ( 14 C) labeled compounds are particularly preferred due to their ease of preparation and detectability. 2 Substitution with heavier isotopes, such as H, can confer certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and therefore may be preferred in some circumstances. The isotopically labeled compounds disclosed herein, including pharmaceutical salts, esters and prodrugs thereof, can be prepared by any means known in the art.
[0063] In addition, the usual abundance of hydrogen ( 1 Substitution of heavier isotopes, such as deuterium, for hydrogen (H) may provide certain therapeutic advantages (e.g., resulting from improved absorption, distribution, metabolism and / or excretion (ADME) properties) and may create drugs with improved efficacy, safety and / or tolerability. 12 C 13 C. See WO 2007 / 005643, WO 2007 / 005644, WO 2007 / 016361 and WO 2007 / 016431.
[0064] The term "hydrogen" refers to all hydrogen isotopes, including protium and deuterium. In a given composition, the hydrogen molecules may be all protium, all deuterium, or a mixture of both, unless otherwise specified.
[0065] All stereoisomers (e.g., cis and trans isomers) and all optical isomers (e.g., R and S enantiomers) of the compounds disclosed herein, as well as racemic, diastereomeric and other mixtures of such isomers. Also within the scope of this disclosure.
[0066] The compounds, salts, esters, prodrugs, hydrates and solvates disclosed herein may exist in several tautomeric forms, including enol and imine forms, and keto and enamine forms, as well as geometric isomers and their mixtures.Tautomers exist as mixtures of soluble tautomer sets.In solid form, one tautomer is usually predominant.Although one tautomer may be described, all tautomers are within the scope of this disclosure.
[0067] Atropisomers are also within the scope of this disclosure, by which is meant compounds that can be separated into isomers with restricted rotation.
[0068] The compounds of the invention, after their preparation, are preferably isolated and purified to obtain compositions containing an amount equal to or greater than 95% by weight ("substantially pure") for use or preparation as described herein. In certain embodiments, the compounds of the invention are greater than 99% pure.
[0069] Solvates of the compounds of the invention are also contemplated herein. Solvates of the compounds of the invention include, for example, hydrates. Detailed Description of the Invention
[0070] The present invention provides compounds and pharmaceutical compositions containing such compounds and their use in the treatment and prevention of diseases and disorders resulting from excess fat accumulation in the liver in mammals, such as simple steatosis and NAFLD, including NASH.
[0071] Specifically, the present invention provides a pharmaceutical composition comprising any compound of the present invention, or a pharma- ceutically acceptable salt, solvate, ester or prodrug thereof, and a pharma- ceutically acceptable excipient, carrier or diluent.
[0072] The present invention also provides a method of treating or preventing non-alcoholic fatty liver disease (NAFLD), e.g., NASH and steatosis, in a mammalian subject, including a human, comprising administering to a mammalian subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising any of the compounds of the present invention described herein, or an enantiomer, diastereomer, tautomer, or a pharma- ceutically acceptable salt, solvate, ester, or prodrug thereof, and a pharma- ceutically acceptable excipient, carrier, or diluent, which is effective in treating or preventing NAFLD in a mammal, including a human.
[0073] In one aspect, the present invention provides methods that result in one or more of the following health benefits from successfully treating or preventing NAFLD or NASH, and optionally their comorbidities: reduction in body weight and BMI; improved liver function; and reduction in at least one of hepatic triglyceride content, hepatic steatosis, inflammation, fibrosis, and liver damage.
[0074] In some embodiments, the present invention generally relates to a compound of formula I [ka] or an enantiomer, diastereomer, tautomer, or pharma- ceutically acceptable salt or solvate thereof for the therapeutic or prophylactic treatment of NAFLD, including NASH and simple steatosis, wherein the symbols have the following meanings, selected independently for each occurrence: And, R1 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2OR e , C(=O) OR d , C(=O)R a or C(=O)NR b R c and R2 is a heterocycle or substituted heterocycle, aryl or substituted aryl; R3 is hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl; R4, R7, and R8 each independently represent hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and R5 is alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, amino or substituted amino; R6 is hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR a and R a is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; R b , R c and R d are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or b and R c optionally form a heterocyclic or substituted heterocyclic ring together with the N to which they are attached; R e is an alkyl or substituted alkyl, an alkenyl or substituted alkenyl, an alkynyl or substituted alkynyl, a cycloalkyl or substituted cycloalkyl, a cycloalkyl cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl.
[0075] In some embodiments, the present invention generally relates to a compound of formula II [ka] or an enantiomer, diastereomer, tautomer, or pharma- ceutically acceptable salt or solvate thereof for the therapeutic or prophylactic treatment of NAFLD, including NASH and simple steatosis, wherein the symbols have the following meanings and are independently selected for each occurrence: Het is a 5- or 6-membered aromatic ring containing at least one heteroatom selected from N, O and S; R1 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a or C(=O)NR b R c and R3 and R 10 are each independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl; R4, R7, and R8 are each independently hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b Rc , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and R5 is alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, amino or substituted amino; R6 and R9 are each independently hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or ORa; R 14 and R 15 are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or optionally, 14 and R 15 together with the N to which they are attached form a heterocyclic ring or a substituted heterocyclic ring, Ra is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkyl or cycloalkyl; alkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; R b , R c and R d are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or optionally, b and Rc together with the N to which they are attached form a heterocyclic ring or a substituted heterocyclic ring, R e is alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl.
[0076] In some embodiments, the present invention generally relates to a compound of formula III [ka] or an enantiomer, diastereomer, tautomer, or pharma- ceutically acceptable salt or solvate thereof for the therapeutic or prophylactic treatment of NAFLD, including NASH and simple steatosis, wherein the symbols have the following meanings and are independently selected for each occurrence: Het is a 5- or 6-membered aromatic ring containing at least one heteroatom selected from N, O and S; R1 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a or C(=O)NR b R c and R3 and R 10 are each independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl; R4, R7, and R8 each independently represent hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and R5 is alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, amino or substituted amino; R6 and R9 are each independently hydrogen, halogen, cyano, nitro, CF3, OCF3 , alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR a and R 11 is hydrogen or C 1~4 is alkyl, R 12 and R 13 are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or 12 and R 13 optionally form a heterocyclic or substituted heterocyclic ring together with the N to which they are attached; n is an integer selected from 2, 3, 4, 5, and 6; R a is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; R b , R c and R d are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or b and R c optionally form a heterocyclic or substituted heterocyclic ring together with the N to which they are attached; R e is alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl.
[0077] In some embodiments, the present invention generally relates to a compound of formula IV [ka] or an enantiomer, diastereomer, tautomer, or pharma- ceutically acceptable salt or solvate thereof for the therapeutic or prophylactic treatment of NAFLD, including NASH and simple steatosis, wherein the symbols have the following meanings and are independently selected for each occurrence: Het is a 5- or 6-membered aromatic ring containing at least one heteroatom selected from N, O and S; R1 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a or C(=O)NR b R c and R3 and R 10 are each independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl; R4, R7, and R8 each independently represent hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkane, nyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b Rc , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and R5 is alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, amino or substituted amino; R6 and R9 are each independently hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR a and R 14 and R 15 are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or 14 and R 15 optionally form a heterocyclic or substituted heterocyclic ring together with the N to which they are attached; R ais hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; R b , R c and R d are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or b and R c optionally form a heterocyclic or substituted heterocyclic ring together with the N to which they are attached; R e is alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl.
[0078] In some embodiments, the present invention generally relates to a compound of formula V [ka] or an enantiomer, diastereomer, tautomer, or pharma- ceutically acceptable salt or solvate thereof for the therapeutic or prophylactic treatment of NAFLD, including NASH and simple steatosis, wherein the symbols have the following meanings and are independently selected for each occurrence: R1 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2ORe , C(=O ) OR d , C(=O)R a or C(=O)NR b R c and R3 and R 10 are each independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl; R4, R7, and R8 each independently represent hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NRb R c , N.R. b C(=O)R a or NR b P(=O)2R e and R5 is substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, amino or substituted amino; R6 and R9 are each independently hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR a and R 11 is hydrogen or C 1~4 is alkyl, R 12 and R 13 are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or 12 and R 13 optionally form a heterocyclic or substituted heterocyclic ring together with the N to which they are attached; n is an integer selected from 2, 3, 4, 5, and 6; R a is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; R b , R c and R d are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or b and R c optionally form a heterocyclic or substituted heterocyclic ring together with the N to which they are attached; R eis alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl.
[0079] In various embodiments, the compound of the invention is one of the following eight compounds: [ka] [ka]
[0080] Item 1. In some embodiments, the present invention generally provides a compound of formula VI [ka] or an enantiomer, diastereomer, tautomer, or pharma- ceutically acceptable salt or solvate thereof for the therapeutic or prophylactic treatment of NAFLD, including NASH and simple steatosis, During the ceremony, R1 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a or C(=O)NR b R c and R2 is a monocyclic or bicyclic heterocycle or substituted heterocycle, aryl or substituted aryl; R3 is hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, halogen, -OR a , -C(O)R a , -C(O)OR a , -NR a R b , or S(O)NR a R b R4, R5, R6 and R7 are each independently hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b Rc , N.R. b C(=O)R a or NR b P(=O)2R e and T is O, S or R a and U, V and W are each independently carbon, N, O or S; X, Y, Z and A are each independently carbon or N, with the proviso that the ring in which X, Y, Z and A occur is aromatic; provided that one of R4, R5, R6 and R7 is a substituted heterocycle or a substituted aryl, and when X, Y, Z or A is a heteroatom, R4, R5, R6 or R7 is absent, and the substituted heterocycle and substituted aryl in R4, R5, R6 and R7 are each selected from the following groups: [ka] and During the ceremony Q-2 is a heterocycle, C(=O)NR b R c or aryl, R n’ , R n’’ and R n’’’ each independently represents hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, OR a , S.R. a , C(=O)R a , C(=O)OR a , NH2, S(O)2NH2, NR b R c , a heterocycle or a substituted heterocycle or an aryl or a substituted aryl; R a is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkyl nyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; Rb , R c and R d are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or optionally, b and R c together with the N to which they are attached form a heterocycle or a substituted heterocycle; R e is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl.
[0081] Item 2. The compound according to item 1, wherein T is O or S: [ka]
[0082] Item 3. The compound according to item 2, wherein T is O: [ka]
[0083] Item 4. The compound according to item 2, wherein V is carbon: [ka]
[0084] Item 5. The compound according to Item 2, wherein W is N: [ka]
[0085] Item 6. The compound according to item 5, wherein T is O and W is N: [ka]
[0086] Item 7. The compound according to item 4, wherein T is O and V is carbon: [ka]
[0087] Item 8. The compound according to item 1, wherein U is carbon, V is carbon, W is N, and T is O: [ka]
[0088] Item 9. The compound according to any one of items 1 to 8, wherein each of X, Y, Z and A is carbon.
[0089] Item 10. The compound according to any one of items 1 to 9, wherein R1 is hydrogen.
[0090] Item 11. R2 is [ka] wherein Q-1 is a heterocycle or an aryl; R 2’ , R 2’’ , R 2’’’ and R 2’’’’ are each independently absent, hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR a , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b Rc , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e The compound according to any one of items 1 to 10,
[0091] Item 12. The compound according to item 10 or 11, wherein at least one of X, Y, Z and A is a heteroatom.
[0092] Item 13. The compound according to any one of items 10 to 12, wherein Q-1 is heteroaryl.
[0093] Item 13'. The compound according to any one of Items 10 to 12, wherein Q-1 is phenyl.
[0094] Item 14. Q-1 is pyrrole, furan, thiophene, pyridine, pyrimidine, pyrazine, pyridazine, imidazole, indole, pyrrolopyridinone, pyridone, pyrrolidine 14. The compound according to item 13, wherein the compound is selected from the group consisting of pyridinones, pyridinones, piperidines and pyrroloazepinones.
[0095] Item 15. The compound according to item 14, wherein Q-1 is selected from the group consisting of pyrrole, furan, thiophene, pyridine, pyrimidine, pyrazine, pyridazine, imidazole, indole, and pyrrolopyridinone.
[0096] Item 16. The compound according to item 15, wherein Q-1 is pyrrole.
[0097] Item 17. The compound according to item 13, wherein Q-1 is pyridone, pyrrolidine, pyridinone or piperidine.
[0098] Item 18. The compound according to item 17, wherein Q-1 is a pyridone or pyridinone.
[0099] Item 19.R 2’ , R 2’’ , R 2’’’ and R 2’’’’ are independently absent, hydrogen, alkyl, substituted alkyl, substituted heterocycle, substituted aryl, C(=O)OR e or C(=O)NR b R c and During the ceremony R b and R c are independently hydrogen, alkyl, substituted alkyl, substituted heterocycle, or optionally, b and R c form a heterocycle or a substituted heterocycle together with the N to which they are attached; R e is hydrogen, The compound according to any one of items 11 to 18.
[0100] Item 20.R 2’ , R 2’’ , R 2’’’ and R 2’’’’ One of them is C(=O)NR b R c where R b is hydrogen, R c is NR bn R cn (R in the formula bn and R cn is alkyl, or optionally, bn and Rcn are taken together with the N to which they are attached to form a substituted heterocycle, said heterocycle being piperidine or morpholine, or optionally R b and R c together with the N to which they are attached form a substituted heterocycle, said heterocycle being piperidine or morpholine; R 2’ , R 2’’ , R 2’’’ and R 2’’’’ 20. The compound according to item 19, wherein two of are independently alkyl and the other is hydrogen.
[0101] Item 21.R 2’ , R 2’’ , R 2’’’ and R 2’’’’ One of them is C(=O)NR b R c where: NR b R c 21. The compound according to item 20, wherein is 2-(di-ethylamino)ethyl, amino, 2-pyrrolidinoethylamino, 4-methylpiperazinyl or morpholino.
[0102] Item 21'. Q-1 is pyrrole, R 2’ , R 2’’ , R 2’’’ and R 2’’’’ does not exist and R 2’ , R 2’’ , R 2’’’ and R 2’’’’ Two of the are alkyl (e.g., methyl), and R 2’ , R 2’’ , R 2’’’ and R 2’’’’ One of them is C(=O)NR b R c Item 17. The compound according to item 16, wherein
[0103] Item 21''.R b is hydrogen, R c is NRbn R cn (wherein R bn and R cn is alkyl, or optionally, bn and R cn The compound according to item 21', wherein together with the N to which they are attached form a substituted heterocycle, said heterocycle being piperidine or morpholine.
[0104] Item 21'''.NR b R c The compound according to item 21'', wherein is 2-(di-ethylamino)ethyl, amino or 2-pyrrolidinoethylamino.
[0105] Item 21''''. If necessary, R b and R c together with the N to which they are attached form a heterocycle or a substituted heterocycle.
[0106] Item 21'''''.NR b R c is 4-methylpiperazinyl or morpholino.
[0107] Item 22. R4, R5, R6 and R7 are each independently hydrogen, halogen, cyano, nitro, alkyl or substituted alkyl, OR a , N.R. b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,or [ka] 22. The compound according to any one of items 1 to 21, wherein
[0108] Item 23. R4, R5, R6 and R7 are each independently hydrogen, halogen, cyano, nitro, alkyl, ORa , N.R. b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c (In the ceremony R a is hydrogen, or alkyl or substituted alkyl; R b and R c are independently hydrogen, or alkyl or substituted alkyl; R e is alkyl or substituted alkyl, optionally substituted with one or more substituents selected from the group consisting of hydroxy, amino, nitro, cyano, halogen, alkoxy, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, aryl, cycloalkyl, and heterocycle; and [ka] 23. The compound according to any one of items 1 to 22, wherein
[0109] Item 24. One of R4, R5, R6 and R7 is [ka] and the others of R4, R5, R6 and R7 are each independently hydrogen.
[0110] Item 25. The compound according to item 24, wherein Q-2 is selected from the group consisting of pyrrole, furan, thiophene, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, triazole, thiadiazole, oxadiazole, pyrrolidine, piperidine, azepane, tetrahydrofuran, oxane, oxepane, indole, indolinone, indazole, benzothiazole, quinoline, quinazoline, quinoxaline, imidazopyridine, imidazopyridazine, pyrazolopyridine, pyrazolopyrimidine, phthalazinone and phenyl.
[0111] Item 26. The compound according to item 25, wherein Q-2 is selected from the group consisting of pyrrole, furan, thiophene, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, triazole, thiadiazole, oxadiazole, pyrrolidine, piperidine, azepane, tetrahydrofuran, oxane, oxepane, indole, indolinone, indazole, benzothiazole, quinoline, quinazoline, quinoxaline, imidazopyridine, imidazopyridazine, pyrazolopyridine, pyrazolopyrimidine and phthalazinone.
[0112] Item 27. The compound according to item 26, wherein Q-2 is selected from the group consisting of thiophene, imidazole, oxazole, thiazole, thiadiazole, piperidine and pyrazole.
[0113] Item 27'. The compound according to item 26, wherein Q-2 is selected from the group consisting of indole, indolinone, indazole, benzothiazole, quinoline, quinazoline, quinoxaline, imidazopyridine, imidazopyridazine, pyrazolopyridine, pyrazolopyrimidine and phthalazinone.
[0114] Item 28. The compound according to item 27, wherein Q-2 is thiazole.
[0115] Item 29. The compound according to Item 27, wherein Q-2 is imidazole.
[0116] Item 30. The compound according to Item 27, wherein Q-2 is piperidine.
[0117] Item 31. The compound according to Item 27, wherein Q-2 is pyrazole.
[0118] Item 32.R n’ is pyrrolidinyl, piperidinyl, azepanyl, tetrahydrofuranyl, oxanyl, oxepanyl, pyranyl, phenyl, thiophenyl, pyrazinyl, pyrimidinyl, pyridazinyl or pyridyl, optionally wherein the piperidinyl, pyranyl, phenyl, thiophenyl, pyrazinyl, pyrimidinyl, pyridazinyl and pyridyl are selected from the group consisting of halogen, cyano, nitro, alkyl or substituted alkyl, OR a , N.R. b R c , C(= O)OR e , C(=O)R a or C(=O)NR b R c (wherein R a is hydrogen or alkyl or substituted alkyl; R b and R c are independently hydrogen, or alkyl or substituted alkyl, and R e is alkyl or substituted alkyl, optionally substituted with one or more substituents selected from the group consisting of hydroxy, amino, nitro, cyano, halogen, alkoxy, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, aryl, cycloalkyl, and heterocycle; R n’’ and R n’’’ is independently hydrogen, or alkyl or substituted alkyl (optionally substituted alkyl with one or more substituents selected from the group consisting of hydroxy, amino, nitro, cyano, halogen, alkoxy, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, aryl, cycloalkyl and heterocycle).
[0119] Item 32'.R n’ , R n’’ and R n’’’ 26. The compound according to any one of items 22 to 25, wherein is independently hydrogen, alkyl or methoxy.
[0120] Item 32''.R n’ , R n’’ and R n’’’ and each are hydrogen.
[0121] Item 33.R n’ pyrrolidinyl, piperidinyl, tetrahydrofuranyl, pyranyl, phenyl, pyrazinyl, pyrimidinyl or pyridyl, whereby the piperidinyl, pyranyl, phenyl, pyrazinyl, pyrimidinyl and pyridyl are optionally selected from the group consisting of halogen, cyano, alkyl or substituted alkyl, OR a ORC(=O)OR e (wherein R a is hydrogen, or alkyl or substituted alkyl; R e is alkyl or substituted alkyl (optionally substituted alkyl with one or more substituents selected from the group consisting of hydroxy, amino, nitro, cyano, halogen, alkoxy, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, aryl, cycloalkyl, and heterocycle); R n’’ and R n’’’ is independently hydrogen, alkyl or amino.
[0122] Item 33'.R n’ is phenyl or substituted phenyl, R n’’ and R n’’’ is independently hydrogen, or alkyl or amino.
[0123] Item 34.R n’’ and R n’’’ is independently hydrogen or alkyl.
[0124] Item 35. Q-2 is based on the following criteria: [ka] 34. The compound according to claim 32 or 33, selected from the group consisting of:
[0125] Item 36. Q-2 is based on the following criteria: [ka] 34. The compound according to item 32 or 33, selected from the group consisting of:
[0126] Item 37. The compound, [ka] The compound according to any one of claims 1, selected from the group consisting of:
[0127] In some embodiments, the present invention generally relates to a compound of formula VII [ka] or an enantiomer, diastereomer, tautomer, or pharma- ceutically acceptable salt or solvate thereof for the therapeutic or prophylactic treatment of NAFLD, including NASH and simple steatosis, During the ceremony R1 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl, aryl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2OR e , C(=O)OR d, C(=O)R a or C(=O)NR b R c and R3 is hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, halogen, -OR a , -C(O)R a , -C(O)OR a , -NR a R b , or S(O)NR a R b R4, R6 and R7 are each independently hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NRb R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and X, Z and A are each independently carbon or N, with the proviso that the ring in which X, Z and A occur is aromatic; Q-1 and Q-2 are independently a heterocycle, C(=O)NR b R c or aryl, R 2’ , R 2’’ , R 2’’’ and R 2’’’’ each independently is absent, hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR a , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)Ra or NR b P(=O)2R e and R 5’ , R 5’’ and R 5’’’ are each independently hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, OR a , S.R. a , C(=O)R a , C(=O)OR a , NH2, S(O)2NH2, NR b R c , a heterocycle or a substituted heterocycle or an aryl or a substituted aryl; During the ceremony R a is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; R b , R c and R d are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or optionally, b and R c together with the N to which they are attached form a heterocycle or a substituted heterocycle; R e is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl.
[0128] In some embodiments, the compound of formula (VII) wherein each of X, Z and A is carbon. In some embodiments, the compound of formula (VII) wherein one of X, Z and A is a heteroatom.
[0129] In some embodiments, the compound of formula (VII) has the formula (VII-a): [ka] wherein R1, R 2’ , R 2’’、 R 2’’’、 R 2’’’’ , R3, R4, R 5’ , R 5’’ , R 5’’’ , R6, R7, X, Ql and Q-2 are the same as defined above.
[0130] In some embodiments, the compound of formula (VII) has the formula (VII-b): [ka] wherein R 2’ , R 2’’ , R 2’’’ are each independently absent, hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR a , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR bR c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and R 2’’’ is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a , C(=O)NR b R c and R1, R3, R 4、 R 5’、 R 5’’ , R 5’’’ , R6, R7, X and Q-2 are This is the same as the definition above.
[0131] In some embodiments, the compound of formula (VII-b) wherein X is C. In some embodiments, the compound of formula (VII-b) wherein X is N. In some embodiments, the compound of formula (VII-b) wherein R 2’’’’ is H. In some embodiments, R 2’’ and R 2’’’ is independently hydrogen. 2’’ and R 2’’’ each is independently methyl.
[0132] In some embodiments, the compound of formula (VII) has the formula (VII-c): [ka] wherein R1, R 2’ , R 2’’、 R 2’’’、 R 2’’’’ , R3, R4, R 5’ , R 5’’ , R6, R7, X and Q-1 are the same as defined above.
[0133] In some embodiments, the compound of formula (VII) has the formula (VII-d): [ka] wherein X is C or N; R 2’ , R 2’’ , R 2’’’ are each independently absent, hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl. OR a , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. dS(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and R 2’’’ is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a , C(=O)NR b R c and R1, R3, R 4、 R 5’、 R 5’’ , R6 and R7 are defined as above.
[0134] In some embodiments, the compound of formula (VII) has the formula (VII-e): [ka] wherein Z is C or N; R1, R 2’ , R 2’’、 R 2’’’、 R 2’’’’ , R3, R4, R 5’ , R 5’’ , R 5’’’ , R6, R7, Ql and Q-2 are the same as defined above.
[0135] In some embodiments, the compound of formula (VII) has the formula (VII-f): [ka] wherein Z is C or N; R 2’ , R 2’’ , R 2’’’ are each independently absent, hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR a , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and R 2’’’ is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a, S.R. a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a , C(=O)NR b R c and R1, R3, R4, R 5’ , R 5’’ , R 5’’’ , R6, R7 and Q-2 are the same as defined above.
[0136] In some embodiments, the compound of formula (VII-f) wherein Z is C. In some embodiments, the compound of formula (VII-f) wherein Z is N. In some embodiments, the compound of formula (VII-f) wherein R 2’’’’ is H. In some embodiments, R 2’’ and R 2’’’ Each of is independently hydrogen. 2’’ and R 2’’’ each is independently methyl.
[0137] In some embodiments, the compound of formula (VII) has the formula (VII-g): [ka] wherein Z is C or N; R1, R 2’ , R 2’’、 R 2’’’、 R 2’’’’ , R3, R4, R 5’ , R 5’’ , R6, R7 and Q-1 are the same as defined above.
[0138] In some embodiments, the compound of formula (VII) has the formula (VII-h): [ka] wherein Z is C or N; R 2’ , R 2’’ , R 2’’’ are each independently absent, hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR a , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and R 2’’’ is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R.a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a , C(=O)NR b R c and R1, R3, R 4、 R 5’、 R 5’’ , R6 and R7 are defined as above.
[0139] In some embodiments, the compound of formula (VII) has the formula (VII-i): [ka] wherein A is C or N; R1, R 2’、 R 2’’、 R 2’’’ , R 2’’’’ , R3, R4, R 5’ , R 5’’ , R 5’’’ , R6, R7, Ql and Q-2 are the same as defined above.
[0140] In some embodiments, the compound of formula (VII) has the formula (VII-j): [ka] wherein A is C or N, R 2’ , R 2’’ , R 2’’’ are each independently absent, hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR a , N.R. b R c , N.R. b S(=O)2R e , N.R.b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and R 2’’’ is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a , C(=O)NR b R c and R1, R3, R 4、 R 5’、 R 5’’ , R 5’’’ , R6, R7 and Q-2 are the same as defined above.
[0141] In some embodiments, the compound of formula (VII-j) wherein A is C. In some embodiments, the compound of formula (VII-j) wherein A is N. In some embodiments, the compound of formula (VII-j) wherein R 2’’’’ is H. In some embodiments, R 2’’ and R 2’’’ is independently hydrogen. 2’’ and R 2’’’ each is independently methyl.
[0142] In some embodiments, the compound of formula (VII) has the formula (VII-k): [ka] wherein A is C or N; R1, R 2’ , R 2’’、 R 2’’’、 R 2’’’’ , R3, R4, R 5’ , R 5’’ , R6, R7 and Q-1 are the same as defined above.
[0143] In some embodiments, the compound of formula (VII) has the formula (VII-l): [ka] wherein A is C or N; R 2’ , R 2’’ , R 2’’’ are each independently absent, hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR a , N.R. b R c , N.R. bS(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and R 2’’’ is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a , C(=O)NR b R c and R1, R3, R 4、 R 5’、 R 5’’ , R6 and R7 are defined as above.
[0144] In some embodiments, the compound of formula (VII) has the formula (VII-m): [ka] wherein R1, R 2’ , R 2’’、 R 2’’’、 R 2’’’’ , R3, R4, R 5’ , R 5’’ , R 5’’’ , R6 and R7 are defined as above.
[0145] In some embodiments, the compound of formula (VII) has the formula (VII-n): [ka] wherein R1, R 2’ , R 2’’、 R 2’’’、 R 2’’’’ , R3, R4, R 5’ , R 5’’ , R 5’’’ , R6 and R7 are defined as above.
[0146] In some embodiments, the compound of formula (VII) has the formula (VII-o): [ka] wherein R1, R 2’ , R 2’’、 R 2’’’、 R 2’’’’ , R3, R4, R 5’ , R 5’’ , R 5’’’ , R6 and R7 are defined as above.
[0147] In some embodiments, the present invention generally relates to a compound of formula VIII [ka] or an enantiomer, diastereomer, tautomer, or pharma- ceutically acceptable salt or solvate thereof for the therapeutic or prophylactic treatment of NAFLD, including NASH and simple steatosis, During the ceremony R1 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a or C(=O)NR b R c and R3 is hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, halogen, -OR a , -C(O)R a , -C(O)OR a , -NR a R b , S(O)NR a R b and R4, R5 and R7 each independently represent hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e, N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and X, Y and A are each independently carbon or N, with the proviso that the ring in which X, Y and A reside is aromatic; Q-1 and Q-2 are independently a heterocycle, C(=O)NR b R c or aryl, R 2’ , R 2’’ , R 2’’’ and R 2’’’’ each independently is absent, hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR a , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b Rc , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and R 6’ , R 6’’ and R 6’’’ each independently represents hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, OR a , S.R. a , C(=O)R a , C(=O)OR a , NH2, S(O)2NH2, a heterocycle or a substituted heterocycle or an aryl or a substituted aryl; During the ceremony R a is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; R b , R c and R d are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or optionally, b and R ctogether with the N to which they are attached form a heterocycle or a substituted heterocycle; R e is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl.
[0148] In some embodiments, the present invention generally relates to a compound of formula IX [ka] or an enantiomer, diastereomer, tautomer, or pharma- ceutically acceptable salt or solvate thereof for the therapeutic or prophylactic treatment of NAFLD, including NASH and simple steatosis, During the ceremony R1 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a or C(=O)NR b R c and R3 is hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, halogen, -OR a , - C(O)R a , -C(O)OR a , -NR a R b or S(O)NR a R b and R4, R5 and R6 each independently represent hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and X, Y and Z are each independently carbon or N, with the proviso that the ring in which X, Y and Z occur is aromatic; Q-1 and Q-2 each independently represent a heterocycle, C(=O)NR b Rc or aryl, R 2’ , R 2’’ , R 2’’’ and R 2’’’’ each independently is absent, hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR a , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and R 7’ , R 7’’ and R 7’’’ each independently represents hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, OR a , S.R. a , C(=O)R a , C(=O)OR a, NH2, S(O)2NH2, a heterocycle or a substituted heterocycle or an aryl or a substituted aryl; During the ceremony R a is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; R b , R c and R d are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or optionally, b and R c together with the N to which they are attached form a heterocycle or a substituted heterocycle; R e is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl.
[0149] In some embodiments, the present invention generally relates to a compound of formula X [ka] or an enantiomer, diastereomer, tautomer, or pharma- ceutically acceptable salt or solvate thereof for the therapeutic or prophylactic treatment of NAFLD, including NASH and simple steatosis, During the ceremony R1 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R.a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a or C(=O)NR b R c and R3 is hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, halogen, -OR a , -C(O)R a , -C(O)OR a , -NR a R b or S(O)NR a R b and R5, R6 and R7 each independently represent hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)ORe , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and Y, Z and A are each independently carbon or N, with the proviso that the ring in which Y, Z and A occur is aromatic; Q-1 and Q-2 are independently a heterocycle, C(=O)NR b R c or aryl, R 2’ , R 2’’ , R 2’’’ and R 2’’’’ each independently is absent, hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR a , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b Rc , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and R 4’ , R 4’’ and R 4’’’ are each independently hydrogen, halogen, cyano, nitro trihalomethyl, OCF3, alkyl or substituted alkyl, OR a , S.R. a , C(=O)R a , C(=O)OR a , NH2, S(O)2NH2, a heterocycle or a substituted heterocycle or an aryl or a substituted aryl; During the ceremony R a is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; R b , R c and R d are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or optionally, b and R c together with the N to which they are attached form a heterocycle or a substituted heterocycle; R e is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl.
[0150] In various embodiments, the compound of the invention is one of the following 15 compounds: [ka] [ka] synthesis
[0151] Exemplary methods for preparing the compounds of the invention are described in the sections that follow, but the invention is not intended to be limited thereto.
[0152] In the following exemplary methods for chemically synthesizing the compounds of the invention, the starting materials and the intermediates of the reactions can be isolated and purified if desired using conventional techniques, including but not limited to filtration, distillation, crystallization, chromatography, and the like.
[0153] The materials of the present invention can be characterized by conventional means, including, but not limited to, physical constants and spectral data. The reactions are performed in solvents appropriate to the reagents and materials employed and suitable for the transformations being effected. Representative examples include tetrahydrofuran, dimethylformamide, methanol, ethanol, water, dimethylformamide, chloroform, dichloromethane, hexane, toluene, 1,4-dioxane. or ethyl acetate, but are not limited to.
[0154] Unless specified, reactions described herein were carried out over a temperature range of about -78°C to about 150°C at atmospheric pressure.
[0155] For heating, any method can be used depending on the reagents and target materials, typical examples include, but are not limited to, a water bath, an oil bath, a water bath or a microwave reactor.
[0156] In the present invention, the compound of formula VI can be prepared from known compounds by the following Preparation Methods I-II, methods similar to the following Preparation Methods, or by combining syntheses known to those skilled in the art as necessary.
[0157] Preparation method
[0158] Compounds of formula VI may be synthesized by the following method. [ka]
[0159] In the scheme, R1, R2, R3, R4, R5, R6, R7, T, U, V, W, X, Y, Z, A, R n’ , R n’’ , R n’’’ and Q-2 is VI-1 and VIII-1, in which R4, R5, R6 and R7 are [ka] As defined above for formula V1, except that: J is a metal-containing group such as boronic acid, boronic acid pinacol ester, trifluoroborane, organotin, zinc halide, magnesium halide, organosilicon, and organolithium. K is a leaving group such as Cl, Br, I, and OTf.
[0160] Preparation method I
[0161] The compounds of the present invention may be synthesized using the following methods.
[0162] Of the compounds of formula VI, compound VI-3 or a pharma- ceutically acceptable salt thereof is prepared by the following method. [ka]
[0163] In the Schemes, the symbols have the same meaning as defined above.
[0164] The compound of formula VI-1 can be reacted with a compound of formula VI-2 in the presence of a transition metal catalyst (representative examples include, but are not limited to, tetrakis(triphenylphosphine)palladium(0), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride, palladium on carbon, dichlorobis(triphenylphosphine)nickel(II), or bis(triphenylphosphine)palladium(II) dichloride), an alkali metal carbonate (representative examples include, but are not limited to, potassium carbonate, sodium carbonate, or cesium carbonate), or other alkali metal salts (sodium hydroxide, potassium hydroxide, sodium ethoxide, sodium methoxide, sodium tert-butoxide, potassium tert-butoxide, sodium hydride, sodium phosphate, potassium phosphate), and a suitable solvent, or in the absence of a solvent, to give a compound of formula VI-3.
[0165] Preparation method II
[0166] Compound VI-1 can be prepared from compound VII-2. [ka]
[0167] In the Schemes, the symbols have the same meaning as defined above.
[0168] The compound of formula VII-1 can be reacted with a compound of formula VII-2 in the presence of a base (representative examples include, but are not limited to, pyrrolidine and piperidine) or an acid (representative examples include, but are not limited to, hydrochloric acid, acetic acid, trifluoroacetic acid) and a suitable solvent or without a solvent to give a compound of formula VI-1.
[0169] The pharmaceutical compositions disclosed herein can be used in animals or humans.The compounds disclosed herein can be formulated as pharmaceutical compositions for oral, buccal, parenteral (e.g., intravenous, intramuscular or subcutaneous), topical, rectal or intranasal administration, or in a form suitable for administration by inhalation or insufflation.The compounds disclosed herein can also be formulated for sustained release according to methods well known to those skilled in the art.Examples of such formulations can be found in U.S. Pat. Nos. 3,119,742, 3,492,397, 3,538,214, 4,060,598 and 4,173,626.
[0170] The formulations may be conveniently presented in unit dosage form and may be prepared by any method known in the pharmaceutical industry. The amount of active ingredient that can be combined with carrier materials to produce a single dosage form varies depending on the animal being treated and the particular mode of administration. The amount of active ingredient that can be combined with carrier materials to produce a single dosage form will generally be the amount of compound that produces a therapeutic effect. Generally, out of 100%, this amount will range, for example, from about 0.1% to about 25% (e.g., 1%, 2%, 5%, 10%, 15%, 20%) of active ingredient.
[0171] Therapeutic compositions or formulations of the present invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (with flavored bases, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as a lozenge (with an inert base, such as gelatin and glycerin, or sucrose and acacia), and / or mouthwash, each containing a predetermined amount of a compound of the present invention as the active ingredient. The compounds of the present invention may also be administered as a bolus, electuary, or paste.
[0172] In solid dosage forms of the invention for oral administration (capsules, tablets, pills, dragees, powders, granules, etc.), the alcohol or inhibitor according to the invention is combined with one or more pharma- ceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and and / or any of the following: fillers or extenders such as starch, lactose, sucrose, glucose, mannitol and / or silicic acid, binders such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and / or acacia, humectants such as glycerol, disintegrants such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, sodium carbonate and sodium starch glycolate, solution retarders such as paraffin, absorption accelerators such as quaternary ammonium compounds, wetting agents such as cetyl alcohol, glycerol monostearate and polyethylene oxide-polypropylene oxide copolymers, absorbents such as kaolin and bentonite clay, lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate and mixtures thereof, and colorants. In the case of capsules, tablets and pills, the pharmaceutical composition may also contain buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar, as well as high molecular weight polyethylene glycols and the like.
[0173] The liquid dosage form for oral administration of the compound of the present invention includes pharma-ceutically acceptable emulsion, microemulsion, solution, suspension, syrup and elixir.In addition to active ingredient, the liquid dosage form may contain inert diluents commonly used in the art, such as solubilizers and emulsifiers, such as water or other solvents, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (especially cottonseed, peanut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycol and fatty acid esters of sorbitan, and mixtures thereof.In addition, cyclodextrins, such as hydroxypropyl-β-cyclodextrin, may be used to solubilize the compound.
[0174] In addition to inert diluents, oral compositions can also contain adjuvants such as wetting agents, emulsifying and suspending agents, sweetening agents, flavoring agents, coloring agents, perfumes and preservatives. In addition to the alcohol or inhibitor according to the invention, suspensions can contain suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
[0175] Formulations of the pharmaceutical compositions of the present invention for rectal or vaginal administration can be prepared by mixing one or more alcohols or inhibitors of the present invention with one or more suitable non-irritating excipients or carriers, including, for example, cocoa butter, polyethylene glycol, suppository wax or salicylates, and can be presented as suppositories that are solid at room temperature but liquid at body temperature and thus melt in the rectum or vaginal cavity and release the active pharmaceutical agent of the present invention.Formulations of the present invention suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers known in the art to be suitable.
[0176] Dosage forms for topical or transdermal administration of an alcohol or other inhibitor according to the present invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions with a pharma- ceutically acceptable excipient, carrier or diluent, including any preservatives, buffers or propellants which may be required.
[0177] For administration intranasally or by inhalation, the compounds disclosed herein may be administered in solution or suspension form from a pump-type spray container that is squeezed or pumped by the patient, or as an aerosol spray presentation from a pressurized container or nebulizer, with the addition of a suitable propellant. The aerosol may be conveniently delivered with the use of, for example, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurized container or nebulizer may contain a solution or suspension of a compound disclosed herein. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated containing a powder mix of a compound disclosed herein and a suitable powder base such as lactose or starch.
[0178] Ointments, pastes, creams and gels may contain, in addition to the alcohol or other inhibitors of the present invention, excipients such as animal and vegetable fats, oils, waxes, paraffins, starches, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonite, silicic acid, talc and zinc oxide or combinations thereof.
[0179] Powders and sprays can contain, in addition to the compounds of the invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
[0180] Ophthalmic formulations, eye ointments, powders, solutions and the like, are also contemplated as being within the scope of the present invention.
[0181] Pharmaceutical compositions of the invention suitable for parenteral administration comprise one or more alcohols or inhibitors according to the invention in combination with one or more pharma- ceutically acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient, or dispersing or thickening agents, or sterile powders which can be reconstituted into sterile injectable solutions or dispersions immediately before use.
[0182] In some cases, it is desirable to delay the absorption of alcohol or inhibitor from subcutaneous or intramuscular injection in order to prolong the effect of alcohol or inhibitor according to the present invention.This can be achieved by using a liquid suspension of crystalline or amorphous material with poor water solubility.The rate of absorption of the drug then depends on its dissolution rate, which in turn can depend on crystal size and crystalline form.Alternatively, delayed absorption of parenterally administered compositions is achieved by dissolving or suspending alcohol or inhibitor in an oil vehicle.One strategy for depot injection includes the use of polyethylene oxide-polypropylene oxide copolymer, a vehicle that is fluid at room temperature and solidifies at body temperature.
[0183] The pharmaceutical compounds of the present invention may be administered alone or in combination with one or more active agents, other medicinal agents, or other agents commonly prescribed or used to treat the symptoms of NAFLD / NASH or its comorbidities, as well as in combination with pharmacologic acceptable excipients, carriers or diluents as described above.
[0184] The amount of pharmacological agent in the oral unit dosage form, as single or multiple doses, is the amount that is effective for treating neurological disorders.As recognized by those skilled in the art, the exact dose to be used will depend on various factors, such as the condition itself, the severity of the condition being treated, the specific composition used, and various physical factors of the individual being treated.In vitro or in vivo assays can be used as necessary to help identify the optimal dosage range.
[0185] The present invention relates to an oral, parenteral, or combination administration to an average adult human for the treatment or prevention of a disease condition. For buccal administration, the proposed dose of the compounds disclosed herein is about 0.1 mg to about 2000 mg. In certain embodiments, the proposed dose is about 0.1 mg to about 200 mg (e.g., 1 mg, 5 mg, 10 mg, 20 mg, 50 mg, 75 mg, 100 mg, 150 mg) of active ingredient per unit dose. Regardless of the proposed dose, administration of the compounds can be performed, for example, 1, 2, 3, or 4 times per day, or 1, 2, 3, 4, or 5 times per week.
[0186] Aerosol formulations for the treatment or prevention of the conditions cited herein for an average adult human are preferably adjusted so that each metered dose or "puff" of aerosol contains about 20 μg to about 10,000 μg, preferably about 20 μg to about 1000 μg (e.g., 25 μg, 50 μg, 100 μg, 200 μg, 500 μg, 750 μg) of a compound disclosed herein. The total daily dose with aerosol will be in the range of about 100 μg to about 100 mg (e.g., 200 μg, 500 μg, 1 mg, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 75 mg). In certain embodiments, the total daily dose with aerosol will generally be in the range of about 100 μg to about 10 mg (e.g., 200 μg, 500 μg, 1 mg, 2 mg, 5 mg, 7.5 mg). Administration may be several times daily, for example 1, 2, 3, 4, 5 or 8 times, giving for example 1, 2 or 3 doses each time.
[0187] The compounds of the present invention can be prepared using the methods described in the present invention, together with synthetic methods known to those skilled in the art of organic synthesis, medicinal chemistry and related fields or modifications thereto. The reactions are carried out in solvents appropriate to the reagents and materials used and suitable for the transformations being carried out. The starting materials of the examples contained herein are commercially available or readily prepared by standard methods from known materials. For example, the following reactions are illustrative and not limiting of the preparation of some of the starting materials and examples used herein. EXAMPLES
[0188] Synthesis Example Preparation of compound 7-1 [ka] To a suspension of 5-chloroacetyloxyindole 1 (42 mg, 0.2 mmol) in EtOH / THF (2 mL / 1 mL) was added thioacetamide 2-1 (15 mg, 0.2 mmol). The mixture was heated at 80° C. for 16 h and then cooled. The solution was purified under vacuum. Concentration gave 3 as an orange solid. 1H NMR (300 MHz,DMSO-d6) δ 10.50 (br. S, 1H), 7.72 - 7.80 (m, 2H),7.33 (s, 1H), 7.16 (s, 1H), 6.86 (d,1H, J = 8.63 Hz), 3.42 - 4.54 (m, 2H);MSm / z 231.10 (M+H).
[0189] To a solution of 3 (53 mg, 0.2 mmol) in EtOH / THF (2 mL / 1 mL) (or using a solution of the reaction mixture above in EtOH / THF (2 mL / 1 mL)), 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid 4 (33.4 mg, 0.2 mmol) and piperidine (21.8 μL) were added. The mixture was heated at 80° C. for 2 h. After cooling to room temperature, the reaction mixture was filtered and washed with EtOH (1 mL) to give a reddish solid 5. 1 HNMR (300 MHz,DMSO-d6) δ 13.80 (s, 1H), 12.10 (br.s, 1H), 11.08 (s, 1H), 8.35(s, 1H), 7.85(s, 1H), 7.78 - 7.81 (m, 2H),6.94 (d, 1H, J = 8.11Hz), 2.74 (s,3H), 2.56 (s, 3H), 2.52 (s, 3H); MS m / z 380.21 (M+H).
[0190] To a solution of 5 (20 mg, 0.052 mmol) in DMF (1.5 mL) was added HATU (24 mg, 0.063 mmol), diisopropylethylamine (30 μL, 0.168 mmol) and 1-methylpiperazine 6-1 (10 μL, 0.090 mmol). The mixture was stirred at room temperature for 16 h and then concentrated in vacuo. The residue was added to CHCl (2 mL) and extracted with HO (3×1.5 mL). The organic layer was dried over NaSO and concentrated in vacuo. The residue was purified by column chromatography (CHCl / MeOH / EtN) to give a yellow solid 7-1. 1HNMR (300 MHz,DMSO-d6) δ 11.00 (s, 1H), 8.30 (s, 1H), 7.83 (s, 1H), 7.65 - 7.78(m, 2H), 6.94 (d, 1H,J = 8.18Hz), 3.02 - 3.20 (m, 4H),2.74 (s, 3H), 2.5 - 2.58(m, 4H),2.5 (s, 6H), 2.3 (s, 3H); MS m / z 462.20 (M+H). Preparation of Compound 10-1 [ka]
[0191] To a suspension of 5-chloroacetyloxyindole 1 (820 mg, 4 mmol) in EtOH / THF (20 mL / 20 mL) was added thiobenzamide 2-2 (550 mg, 4 mmol). The mixture was heated at 80° C. for 16 h and then cooled. The solution was concentrated in vacuo to give an orange solid 8. MS m / z 293.20 (M+H).
[0192] To this solid 8 was added EtOH / THF (20 mL / 20 mL) (or use the reaction mixture above), 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid 4 (668 mg, 4 mmol) and piperidine (400 μL). The mixture was heated at 80° C. for 5 h. After cooling to room temperature, the reaction mixture was filtered and washed with EtOH (1 mL) to give an orange solid 9. 1 HNMR (300 MHz,DMSO-d6) δ 13.80 (s, 1H), 12.40 (s, 1H), 11.10 (s, 1H), 8.47 (s,1H), 8.07 - 8.12 (m, 3H), 7.94 (d, 1H,J = 8.00Hz), 7.86 (s, 1H), 7.55 - 7.6 (m,3H), 7.01 (d, 1H, J = 8.10Hz), 2.59(s, 3H), 2.57 (s, 3H); MS m / z 442.20 (M+H).
[0193] To a solution of 9 (34 mg, 0.077 mmol) in DMF (1.5 mL) was added HATU (35 mg, 0.092 mmol), diisopropylethylamine (30 μL, 0.168 mmol) and 1-methylpiperazine 6-1 (15 μL, 0.13 mmol). The mixture was stirred at room temperature for 16 h and then concentrated in vacuo. The residue was added to CHCl (2 mL) and extracted with HO (3×1.5 mL). The organic layer was dried over NaSO and concentrated in vacuo. The residue was purified by column chromatography (CHCl / MeOH / EtN) to give a yellow solid 10-1. 1 HNMR (300 MHz,DMSO-d6) δ 13.68 (s, 1H), 11.10 (s, 1H), 8.44 (s, 1H), 8.07 -8.10 (m, 3H), 7.91 (d, 1H,J = 8.00Hz), 7.80 (s, 1H), 7.68 - 7.76 (m, 2H), 7.52- 7.58 MS m / z 524.20 (M+H). Preparation of compound 13-3 [ka]
[0194] To a solution of 9 (1.55 g, 3.5 mmol) in DMF (130 mL) was added HATU (1.6 g, 4.2 mmol), diisopropylethylamine (1.6 mL, 9.2 mmol) and N,N-diethyl-1,2-ethanediamine 6-2 (0.6 mL, 4.2 mmol). The mixture was stirred at room temperature for 16 h and concentrated in vacuo. The residue was added to CHCl (800 mL) and extracted with HO (200 mL), saturated NaHCO (200 mL), HO (2×200 mL) and brine (200 mL). The organic layer was dried over NaSO and concentrated in vacuo. The residue was added to a small amount of MeOH and filtered to give a yellow solid 13-3.1 HNMR (300 MHz,DMSO-d6) δ 13.70 (s, 1H), 11.10 (s, 1H), 8.44 (s, 1H), 8.07 - 8.10 (m, 3H), 7.92 (d, 1H,J = 8.10Hz), 7.81 (s, 1H), 7.3 - 7.6 (m, 3H), 7.00(d, 1H, J = 8.10Hz), 3.2 -3.3 (m, 2H), 2.5 - 2.6 (m, 6H), 2.51 (s,3H), 2.48(s, 3H), 1.00 (t, 6H, J = 6.90 Hz); MS m / z 540.20 (M+H). Preparation of compound 18-5 [ka]
[0195] To a solution of solid 12 (44 mg, 0.10 mmol) in DMF (1.5 mL) was added HATU (35 mg, 0.12 mmol), diisopropylethylamine (50 μL, 0.33 mmol) and N,N-diethyl-1,2-ethanediamine 6-2 (23 μL, 0.2 mmol). The mixture was stirred at room temperature for 16 h and concentrated in vacuo. The residue was added to CH2Cl2 (2 mL) and extracted with H2O (1.5 mL). The organic layer was dried over Na2SO4. The residue was purified by column chromatography (CH2Cl2 / MeOH / Et3N) to give a yellow solid 18-5. 1H NMR (400 MHz,DMSO-d6) δ 13.60 (s,1H), 11.00 (s, 1H), 9.18 (d, 1H, J = 1.60Hz), 8.64(dd, 1H, J = 4.80, 1.60 Hz),8.33 - 8.37 (m, 2H), 8.09 (s, 1H), 7.83(dd, 1H, J = 8.00, 1.60 Hz), 7.71 (s,1H), 7.50 (dd, J = 8.00,4.80 Hz, 1H), 7.36 - 7.39 (m, 1H), 6.91 (d, 1H, J =8.00Hz), 3.20 (q, J= 7.10Hz, 4H), 2.4 - 2.6 (m, 4H),0.90 (t, J = 7.10 Hz, 6H);MS m / z 525.20 (M+H).MS m / z 541.20 (M+H).
[0196] Compound 18-5 can be prepared from compound 12 and N,N-diethyl-1,2-ethanediamine 6-2 using a method similar to that used to prepare compound 18-2 in the next example. Preparation of compound 18-2 [ka]
[0197] To a suspension of 5-chloroacetyloxyindole 1 (42 mg, 0.2 mmol) in EtOH / THF (1 mL / 1 mL) was added thionicotinamide 2-3 (27.8 mg, 0.2 mmol). The mixture was heated at 80° C. for 16 h and then cooled. The solution was concentrated in vacuo to give an orange solid 11. MS m / z: 294.20 (M+H).
[0198] This solid 11 was dissolved in EtOH / THF (1 mL / 1 mL), 5-formyl-2,4-dimethyl Chiral-1H-pyrrole-3-carboxylic acid (33.4 mg, 0.2 mmol) and piperidine (21.8 μL) were added. The mixture was heated at 80° C. for 2 h. After cooling to room temperature, the reaction mixture was concentrated and filtered to give an orange solid 12. MS m / z: 443.20 (M+H).
[0199] To a solution of solid 12 (44 mg, 0.10 mmol) in DMF (1.5 mL) was added HATU (35 mg, 0.12 mmol), diisopropylethylamine (50 μL, 0.33 mmol) and 1-methylpiperazine 6-1 (30 μL, 0.26 mmol). The mixture was stirred at room temperature for 16 h and then concentrated in vacuo. The residue was added with CH2Cl2 (2 mL) and extracted with H2O (1.5 mL). The organic layer was dried over Na2SO4 and concentrated in vacuo. The residue was purified by column chromatography (CH2Cl2 / MeOH / Et3N) to give yellow solid 18-2. 1 HNMR (400 MHz, DMSO-d6) δ 13.55 (s, 1H), 11.00 (s, 1H), 9.20(d, 1H, J = 1.60Hz), 8.64 (dd, 1H, J = 4.70, 1.60 Hz), 8.35 -8.37 (m, 2H), 8.10 (s, 1H), 7.84(dd, 1H, J = 8.00, 1.60 Hz), 7.71 (s,1H), 7.52 (ddd, J = 8.00, 4.70, 0.70 Hz,1H), 6.92 (d, 1H, J =8.00 Hz), 3.07 - 3.2 (m, 4H),2.26 (s, 3H), 2.24 (s, 3H), 2.24 - 2.3 (m, 4H), 2.13 (s, 3H);MS m / z:525.20(M+H). Biomedical Assays
[0200] Example 1: Compounds of the invention prevent excess triglyceride accumulation in human hepatocytes
[0201] Preferred embodiments of the compounds of the present invention were evaluated herein for their ability to inhibit fat accumulation in cell culture to determine whether they could be used to treat non-alcoholic fatty liver disease (NAFLD), including more extreme forms of NASH.
[0202] First, a series of in vitro experiments were performed with various human hepatocyte cultures. For example, human HepG2 hepatocytes were incubated with 1.6 mM palmitoleic acid in EMEM medium in the presence of 0.1 μM compound 13-3 or the control vehicle, DMSO, for 48 hours. After 48 hours, cells were harvested and intracellular triglyceride content was measured by a biochemistry kit (Biovision, Mountain View, CA) as described in Derdak et al., J Hepatol. 2013;58(4):785-91. As shown in the figure (Figure 1A), palmitoleic acid treatment substantially increased the intracellular triglyceride content of HepG2 cells, but this event was significantly suppressed by compound 13-3, indicating a strong inhibitory effect on fat accumulation in human hepatocytes.
[0203] The effects on triglyceride accumulation from compounds 13-3-1, 13-3-2, 13-3-3, 13-3-5, 13-3-6, 13-3-7, 18-2, 13-3-10 and 13-3-11 as exemplary compounds of the present invention were tested. Human HepG2 hepatocytes were incubated with 0.8 mM palmitoleic acid in EMEM medium in the presence of 0.1 μM of the compounds of the present invention or control vehicle, DMSO, for 24 hours. Subsequently, the cells were washed with PBS and the intracellular fat content was measured by AdipoRed / Hoechst 33258 double staining, which was evaluated by fluorescence measurement. As shown in the figure (Figure 1B), palmitoleic acid treatment substantially increased the intracellular triglyceride content of HepG2 cells, but this event was significantly suppressed by each of the nine compounds, respectively, showing comparable or greater inhibitory effects on fat accumulation in human hepatocytes compared to compound 13-3.
[0204] The effects of further exemplary compounds of the present invention, Compound 001, Compound 004, Compound 006, Compound 013, Compound 132, Compound 133 and Compound 134, were also tested. In the presence of 0.1 μM of the compounds of the present invention or control vehicle, DMSO, in EMEM medium, Human HepG2 hepatocytes were incubated with 0.8 mM palmitoleic acid for 48 hours. Subsequently, the cells were washed with PBS, and the intracellular fat content was measured by AdipoRed / Hoechst 33258 double staining, which was evaluated by fluorescence measurement. As shown in the figure (Figure 1C), palmitoleic acid treatment substantially increased the intracellular triglyceride content of HepG2 cells, but this event was significantly suppressed by each of the seven deuterated compounds, which showed equal or greater inhibitory effects on fat accumulation in human hepatocytes compared to compound 13-3.
[0205] This observation led to the hypothesis that the compounds of the present invention may have unique liver-directed effects.By directly affecting hepatic fatty acid metabolism, the compounds of the present invention may reduce hepatic steatosis and subsequent liver damage in mice model of NAFLD.To test this hypothesis, the therapeutic efficacy of compound 13-3 in high fat diet (HFD)-induced NAFLD model was evaluated.
[0206] Example 2: Compound 13-3 treatment reduces weight gain in HFD-fed mice without suppressing daily caloric or water intake and significantly ameliorates NAFLD symptoms in a mouse model
[0207] To evaluate the in vivo efficacy of compound 13-3 in improving obesity and ameliorating NAFLD / NASH, a modified high-fat diet (HFD) was used previously to induce obesity and severe fatty liver disease in mice (Derdak et al., Journal of Hepatology 2013;58(4):785-91).
[0208] Five-week-old male C57Bl / 6J mice (12-18 / group, Jackson Laboratory, Bar Harbor, ME) were fed ad libitum with a modified high-fat diet or a control diet (Bioserv, Frenchtown, NJ) for 15 weeks. The caloric profile of the modified HFD (60% of calories from fat) was similar to the composition of a previously published diet that effectively induced obesity, steatosis, and insulin resistance in this mouse strain (Cong et al., Life Sci, 2008;82:983-990). We verified the efficacy of this diet to induce obesity and NAFLD in various pilot studies. At the end of the 15-week feeding regimen, the diet caused substantial ALT elevation in these mice, indicative of liver damage.
[0209] After 15 weeks on the modified HFD, mice were placed on a compound 13-3 (or control vehicle) dosing regimen, receiving an induction dose of 5 mg / kg (orally, 3 times per week for the first 3 weeks) followed by a therapeutic dose of 10 mg / kg (orally, 3 times per week for an additional 5 weeks). Animals were monitored daily for changes in body weight, food / water intake and adverse effects over the course of drug treatment.
[0210] As shown in Figure 2A, compound 13-3 treatment not only prevented further weight gain in HFD mice, but also induced gradual weight loss. As Figure 2B demonstrates, at the time of euthanasia, there was a significant weight difference of about 20% between HFD-fed mice treated with compound 13-3 and HFD-fed mice treated with control vehicle. Furthermore, compound 13-3-induced weight loss in HFD-fed mice was not associated with a decrease in food or water intake (Figures 2C and 2D), indicating that pharmaceutical compositions containing the compounds of the present invention should generally be very safe with few side effects.
[0211] More importantly, compound 13-3 treatment significantly improved NAFLD / NASH symptoms as shown by macroscopic overview of the liver of treated animals at the time of euthanasia (Figure 2E). High-fat diet in vehicle-treated mice promoted hepatomegaly due to ectopic fat accumulation in this organ. The enlarged liver appeared pale yellow, consistent with steatosis. In sharp contrast, compound 13-3 significantly reduced liver size in HFD-fed mice and helped maintain a healthier, darker brown appearance (far right panel). The beneficial effects on liver size and appearance are consistent with the hypothesized anti-NAFLD / NASH effects of compound 13-3, an exemplary compound of the present invention.
[0212] Example 3: Compound 13-3 treatment reduces hepatic steatosis in HFD-fed mice
[0213] Consistent with the inherent hepatotropic effect of compound 13-3 demonstrated by the above experimental examples, dramatic changes in the livers of compound 13-3-treated HFD-fed mice were observed at the time of euthanasia.
[0214] HFD feeding in vehicle-treated mice promoted hepatomegaly due to ectopic fat accumulation in this organ. Figure 3A provides the macroscopic observation that compound 13-3 was able to significantly reduce liver weight and attenuate steatosis in the livers of HFD-fed mice compared to vehicle-treated littermates. This observation was further confirmed by measuring liver weight (Figure 3B) and expressing it in proportion to body weight (Figure 3C). The liver size of HFD-fed mice treated with compound 13-3 was essentially equivalent to that of lean animals, indicating that the compound significantly reduced or prevented ectopic fat accumulation and induced a dramatic regression or inhibition of NASH symptoms in HFD-fed mice.
[0215] Example 4: Compound 13-3 treatment reduces microvesicular and macrovesicular steatosis in HFD-fed mice
[0216] The remarkable efficacy of compound 13-3 in improving NAFLD was further supported by microscopic analysis of harvested liver samples (Figure 4). Hematoxylin-eosin (H&E) staining (top row) revealed disorganized liver architecture, severe microdroplet and macrodroplet steatosis, with hepatocyte ballooning and inflammation (all symptoms of NASH) in livers from HFD-fed vehicle-treated mice in the middle row. All these pathological changes were significantly suppressed by compound 13-3 treatment, as the histology in the right row was remarkably similar to the negative control in the left row, both of which did not show any of these NASH symptoms.
[0217] Furthermore, Masson's Trichrome staining (middle) revealed stage 1 fibrosis in HFD-fed vehicle-treated mice. However, evidence of mild portal and perisinusoidal fibrosis was only found in the HFD-fed vehicle-treated group, whereas HFD-fed mice treated with compound 13-3 did not show any signs of fibrosis.
[0218] Finally, using Periodic Acid Schiff (PAS) staining, it was demonstrated that in the HFD-fed vehicle-treated group, hepatic glycogen was depleted from zones 2 and 3 and replaced by fat, consistent with the development of hepatic insulin resistance. In contrast, there was no evidence of hepatic depletion of glycogen in the livers of HFD-fed compound 13-3-treated mice.
[0219] Example 5: Compound 13-3 significantly reduces NAFLD activity score (NAS) and collagen production
[0220] In this example, the effect of compound 13-3 on the liver was further investigated.
[0221] Microscopic evaluation of hematoxylin-eosin (H&E) stained liver slides was performed by an expert pathologist to determine the effect of drug treatment on NAFLD activity score (NAS) as the primary read-out for the anti-NAFLD efficacy of compound 13-3. A composite NAS score is frequently used to describe the severity of characteristic pathological changes seen in NAFLD / NASH (Kleiner DE et al., Hepatology. 2005;41(6):1313-21), including steatosis, lobular inflammation (Figure 5A), and hepatocyte ballooning (Figure 5B).
[0222] Importantly, NAS scores were substantially lower in compound 13-3-treated HFD-fed mice than in their vehicle-treated littermates (Figure 5C). This dramatic improvement in NAS scores was also associated with a marked decrease in hepatic production of type I collagen α1, as measured by quantitative real-time PCT using a commercially available probe (Thermo Fisher Scientific Inc., Waltham, MA) (Figure 5D). Inhibition of collagen production in the liver indicates that compound 13-3 may also have antifibrotic properties, which is highly favorable for the purpose of treating or preventing NAFLD / NASH. In conclusion, compound 13-3 treatment improves all important aspects of NAFLD / NASH, including steatosis, inflammation, hepatocyte ballooning and fibrosis. Thus, pharmaceutical compositions based on compound 13-3 and other compounds of the present invention are likely to provide a viable treatment for NAFLD, especially NASH.
[0223] Example 6: Compound 13-3 significantly reduces hepatic triglyceride content and liver injury
[0224] The above conclusions of the microscopic findings were also supported by biochemical assays characterizing hepatic triglyceride content (FIG. 6A) and serum ALT / AST levels (FIGS. 6B-6D).
[0225] By using a standard biochemical assay to measure hepatic triglycerides (Biovision, Mountain View, CA), compound 13-3 treatment was shown to prevent HFD-induced steatosis (Figure 6A). This biochemical change is of great importance since ectopic fat accumulation is associated with lipotoxicity and hepatocellular injury. The extent of liver injury has been characterized by measuring serum levels of two liver enzymes, ALT (Figure 6B) and AST (Figure 6C) (UMASS Mouse Phenotyping Center Analytical Core, Worcester, MA), at the time of euthanasia. The observation that the increase in AST levels was less pronounced than that of ALT levels in HFD-fed and vehicle-treated mice indicates that the severity of NAFLD in this animal model may have been moderate (Figures 6B and 6C). Nevertheless, the fact that compound 13-3 treatment was able to largely prevent the dramatic decrease in serum AST:ALT ratio (an indicator of ALT elevation caused by HFD feeding) in HFD-fed vehicle-treated mice (Figure 6D) highlights the profound hepatoprotective effect of the compounds of the invention.
[0226] Example 7: Compound 13-3 increases expression of mediators of fatty acid oxidation and ameliorates leptin resistance in high-fat diet-fed mice
[0227] To study the effect of compound 13-3 on mediators of fatty acid metabolism, we assessed the mediators of fatty acid metabolism in HFD-fed mice treated with compound 13-3 using quantitative real-time PCR using commercially available probes. As shown in Figures 7A-7E, several key mediators of fatty acid oxidation were upregulated, such as CPT1a, an enzyme that catalyzes the rate-limiting step of fatty acid oxidation in mitochondria (Figure 7A), peroxisomal ACOX 1 (Figure 7B) and FGF21, a recently described hepatokine with remarkable anti-NAFLD and hepatoprotective effects (Maratos-Flier E Exp Cell Res (2017) 360(1):2-5; Sonoda J et al., Horm Mol Biol Clin Investig (2017) 30(2); Xu J et al., Diabetes (2009) 58(1):250-259; L Gene expression of FGF21 (see i H et al., Diabetes (2012) 61(4): 797-806; Desai BN et al., Mol Metab (2017) 6(11): 1395-1406) was increased by compound 13-3 treatment in HFD-fed mice. In particular, note the marked increase in FGF21 gene expression shown in Figure 7C. Many of the beneficial metabolic effects are associated with FGF21, and FGF21 itself can further promote fatty acid oxidation (Xu et al., Diabetes (2009) 58(1): 250-259; Li H et al., Diabetes (2012) 61(4): 797-806). Therefore, we also measured serum levels of FGF21 using a commercially available ELISA kit. We found that treatment of HFD-fed mice with compound 13-3 also increased serum FGF21 levels (Figure 7D). These findings suggest that compound 13-3 can activate an intrinsic mechanism that promotes fatty acid oxidation.
[0228] The inhibitory effect of exogenous FGF21 on circulating leptin levels has been previously observed in non-human primates. Therefore, we also measured serum leptin levels using a commercially available ELISA kit. We found that compound 13-3 significantly reduced the HFD-induced increase in leptin levels, indicating the improvement of leptin resistance resulting from treatment with the compound of the present invention (Figure 7E).
[0229] Example 8: Compound 13-3 reduces the expression of key adipogenic targets in fatty liver of high-fat diet-fed mice
[0230] Our data suggest that compound 13-3 can increase the expression of PPAR-α downstream targets (CPT1a, ACOX1) directly involved in fatty acid oxidation and the expression of FGF21, which itself can further enhance fatty acid oxidation (Xu J et al., Diabetes (2009) 58 (1): 250-259; Li H et al., Diabetes (2012) 61 (4): 797-806). FGF21 has also been linked to the suppression of adipogenesis by suppressing hepatic PPAR-γ, FABP4 and CD36 (Xu J et al., Diabetes (2009) 58 (1): 250-259). Given this, we next evaluated the expression of these mediators of adipogenesis in the liver of HFD-fed mice treated with compound 13-3. We found that compound 13-3 suppressed PPAR-γ gene (Figure 8A) and protein expression in the liver, the latter assessed by Western blotting followed by densitometry (Figure 8B), and also reduced gene expression of FABP4 (Figure 8C) and CD36 (Figure 8D), indicative of increased FGF21 signaling. These findings suggest that increased fatty acid oxidation and clearance, together with decreased adipogenesis, are key components of the anti-NAFLD / NASH efficacy of the compounds of the invention.
[0231] In summary, the compound of the present invention, in its representative embodiment as compound 13-3, is an attractive new drug in the treatment of NAFLD, including NASH.The compound of the present invention shows a unique hepatotropic effect observed in both human hepatocyte culture and mouse model in vivo.The compound of the present invention clearly shows the ability to promote fatty acid oxidation and inhibit new fatty acid synthesis. Taken together, these events will lead to the reduction of hepatic steatosis, inflammation, fibrosis and liver damage.Therefore, the compound of the present invention is a very strong candidate in the treatment of NAFLD, including NASH. Equivalent
[0232] The representative examples are intended to aid in the explanation of the invention and are not intended, and should not be construed as, limiting the scope of the invention. Indeed, various modifications of the invention, and many further embodiments thereof, in addition to those shown and described herein, will become apparent to those skilled in the art from the entire contents of this document, as evidenced by the examples and references to the scientific and patent literature herein. The examples contain important additional information, exemplification and guidance that can be adapted to the practice of this invention in its various embodiments and the equivalents thereof.
[0233] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of this disclosure, the preferred methods and materials are described herein. The methods recited herein may be carried out in any order that is logically possible in addition to the specific order disclosed. Incorporation by Reference
[0234] References and citations to other documents, such as patents, patent applications, patent publications, journals, books, literature, web content, etc., have been made in this disclosure. All such documents are incorporated herein by reference in their entirety for all purposes to the maximum extent permitted by law. Although referred to as being incorporated by reference herein, any material or portion thereof that conflicts with existing definitions, references, or other disclosed material that is clearly described herein is incorporated only to the extent that no conflict occurs between the incorporated material and the disclosed material. In case of conflict, the conflict should be resolved in favor of this disclosure as the preferred disclosure.
[0235] According to a preferred embodiment of the present invention, for example, the following is provided: (Section 1) A method for treating non-alcoholic fatty liver disease (NAFLD) in a mammal, including a human, comprising administering to a mammalian subject in need thereof: (a) [ka] [ka] [ka] or an enantiomer, diastereomer, tautomer, or pharma- ceutically acceptable salt, solvate, ester, or prodrug thereof, which is effective in treating or preventing NAFLD in a mammal, including a human, and (b) a pharma- ceutically acceptable excipient, carrier, or diluent; The method of claim 1, further comprising administering (Section 2) A method for treating non-alcoholic fatty liver disease (NAFLD) in a mammal, including a human, comprising administering to a mammalian subject in need thereof: (a) A compound of formula I: [ka] or an enantiomer, diastereomer, tautomer, or pharma- ceutically acceptable salt, solvate, ester, or prodrug thereof, which is effective in treating or preventing NAFLD in a mammal, including a human, comprising a compound of formula I, or an enantiomer, diastereomer, tautomer, or pharma- ceutically acceptable salt, solvate, ester, or prodrug thereof, in a therapeutically effective amount of the compound of formula I, or an enantiomer, diastereomer, tautomer, or pharma- ceutically acceptable salt, solvate, ester, or prodrug thereof, wherein the symbols have the following meanings, independently selected for each occurrence: R 1 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O) 2 R e , S(=O) 2 OR e , C(=O)OR d , C(=O)R a or C(=O)NR b R c and R 2 is a heterocycle or substituted heterocycle, aryl or substituted aryl; R 3 is hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl; R 4 、R 7 and R 8 are each independently hydrogen, halogen, cyano, nitro, or CF 3 , OCF 3 , alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)R e , S(=O) 2 R e , P(=O) 2 R e , S(=O) 2 OR e , P(=O) 2 OR e , N.R. b R c , N.R. b S(=O) 2 R e , N.R. b P(=O) 2 R e , S(=O) 2 NR b R c , P(=O) 2 NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b Rc , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O) 2 NR b R c , N.R. d P(=O) 2 NR b R c , N.R. b C(=O)R a or NR b P(=O) 2 R e and R 5 is alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, amino or substituted amino, R 6 is hydrogen, halogen, cyano, nitro, CF 3 , OCF 3 , alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR a and R a is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; R b 、R c and R d are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or optionally, b and R c together with the N to which they are attached form a heterocyclic ring or a substituted heterocyclic ring, R e is alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; and (b) a pharma- ceutically acceptable excipient, carrier, or diluent; The method of claim 1, further comprising administering (Section 3) A method for treating non-alcoholic fatty liver disease (NAFLD) in a mammal, including a human, comprising administering to a mammalian subject in need thereof: (a) A compound of formula II:
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
Claims
[Claim 1] The invention described in the specification.
Citation Information
Patent Citations
Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
WO2009033033A2
Novel methods for treating cancer
WO2015112941A1
Purification method for 5-(thiazole-4-yl)indoline-2-one derivative
WO2017026119A1
AMA2007
AMA2015
